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ABSTRACT 
 
The alkaloidal content from the leaves of a local Malaysian plant, Ficus fistulosa var. tengerensis 
(Miq.) Kuntze was investigated following a preliminary screening which revealed the presence of 
alkaloids in the plant. However, the bark material was devoid of alkaloids and was thus not 
investigated. The leaves of F. fistulosa var. tengerensis were collected in large scale, dried, ground 
and extracted with 95% ethanol. Acid-base treatment of the ethanolic crude extract followed by 
numerous chromatographic processes resulted in the isolation of five alkaloids. The pure alkaloids 
were subjected to spectroscopic analysis (NMR, UV, IR, X-ray and ECD) for structure elucidation. Of 
the five alkaloids isolated, two were novel alkaloids, namely, (±)-tengerensine (1) and (±)-
tengechlorenine (2). (±)-Tengerensine (1), was isolated as a pair of racemic enantiomers and they 
represent a pair of rare unsymmetrical cyclobutane dimers and the first dimeric 
benzopyrroloisoquinoline alkaloids to be discovered. (±)-Tengechlorenine (2), was isolated as a 
scalemic mixture with a slight excess of the dextrorotatory enantiomer. (±)-Tengechlorenine (2) 
represents the first chlorinated phenanthroindolizidine alkaloid to be isolated. In addition to the two 
new alkaloids, three known alkaloids were also isolated and characterized, viz., ()-fistulosine (3) a 
benzopyrroloisoquinoline alkaloid, (S)-(+)-antofine (4) a phenanthroindolizidine alkaloid, and (R)-()-
secoantofine (5) a septicine-type alkaloid. In vitro antiproliferation assay was carried out on alkaloids 
(±)-1, (+)-1, ()-1 and 3 on a small panel of breast cancer and normal cell lines, including MCF-7, 
MDA-MB-231 and MDA-MB-468 (human breast adenocarcinoma cells), and MCF-10A (non-
tumorigenic breast epithelial cell breast epithelial cells). (+)-Tengerensine 1 was found to display a 
selective cytotoxic effect against MDA-MB-468 cells (IC50 7.4 M), while (±)-1, ()-1 and 3 were 
found to be generally ineffective against all the cell lines tested.  
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Chapter One 
Introduction 
1.1 Natural Products and Drugs Discovery 
Drugs of plant origin have been around since the beginning of recorded history. Ancient civilizations 
are known for their use of plants to make medical remedies. The oldest known written evidence for 
the use of plants as medicines is approximately 5000 years old.1 It was found on a Sumerian clay slab 
near Nagpur based in modern day Iraq. Twelve remedies were made by combining over 250 various 
plants, some of which contain alkaloids, such as Hyoscyamus niger, Mandarke mandragora and 
Papaver somniferum.2 
Emperor Shen Nung “the father of Chinese medicine” wrote a similar book in ca. 2500 BC. The 
Chinese book of roots and grasses “Pen T’sao” contains about 365 different formulations, many of 
which are still used today including; ginseng, jimson weed, cinnamon and ephedra.3,4 
Like other ancient civilizations the ancient Egyptians were known for their medicine and 
pharmacology and they documented the use of plants as drugs. The Ebers Papyrus has more than 
800 remedies of 700 different plant species such as castor oil, aloe, senna, garlic, fig and onion.5 
Other ancient Egyptian known texts include the Edwin Smith Papyrus (1800 BC), the Hearst Papyrus 
(1600 BC) and the London Medical Papyrus (1300 BC). 
Greeks developed the use of medicinal plants and herbs. Theophrastus (ca. 300 BC) studied the 
pharmacology of plants, and wrote one of the most important books of ancient natural history 
“Historia Plantarum” or “history of plants”. In this book, Theophrastus studied the anatomy of plants 
along with their pharmacological use. Another influential western scientist is Dioscorides, who is 
arguably the most prominent writer of ancient medicinal plants and the father of pharmacognosy. 
He studied plants and herbs as he travelled with the Roman army in the “known world” around 75 
AD and wrote his famous book “De Materia Medica” containing over 900 plant medical formulations 
along with detailed description of the plant’s appearance, distribution, cultivation, preparation and 
pharmacological use. Galen (130–200 AD), a Roman physician, pharmacist, surgeon and philosopher, 
published at least 30 books on the subjects of anatomy, physiology and neurology.  
Much of the Greco-Roman medicine knowledge was lost during the Middle Ages, but the Arab and 
the Islamic scholars in Andalusia and the Middle East managed to save and upgrade most of the 
expertise of that era. They improved it by adding their own sources and knowledge of their local 
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plants together with the knowledge of Indian and Chinese medicine. Arabs were also the first in 
history to have private drug stores regulated by the state, where formulations and remedies were 
sold directly to patients. It was around that Islamic golden age where pharmacy flourished and 
advanced as a science. 
This advancement in medicine took place between the 9th and 12th centuries, after which the 
renaissance era started and science began to be studied and developed more in the western world 
(after the fall of the Caliphate Empire in the Middle East). For thousands of years the crude extracts 
of plants were used to treat ailments. This was the case until early 19th century when pharmaceutical 
companies started to commercially sell pure naturally derived compounds as medicines.6 The past 
200 years had witnessed the discovery, isolation and structure elucidation of thousands of natural 
products, of which, hundreds were found to possess tremendous biological activities, and made it to 
the pharmaceutical market for medical use.7 For instance, the first natural product to be isolated 
and used commercially was morphine (6) (potent analgesic) discovered by the German pharmacist 
Friedrich Sertürner from Papaver somniferum.8  
 
 
 
 
 
 
Useful biological activity in organic molecules is considered as a rare property. Therefore, no chemist 
can predict whether any randomly given molecule possess any biological activity. Thus, screening as 
much structures as possible is the only way to determine whether molecules have an effect on 
biological systems or not.9 The extraction of pure natural products and then subjecting them to 
biological assay became the standard process for drug discovery in the early 20th century. In the year 
1928 the first true antibiotic penicillin (7) was extracted from the fungus Penicillium notatum by the 
Scottish pharmacologist Alexander Fleming.7 This discovery revolutionized medicine and the 
treatment of bacterial infection in the 1940s.7,10 Pharmaceutical companies then continued their 
pursue of antibacterial agents discovery from natural sources and managed to discover streptomycin 
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(8), gentamicin (9) and tetracycline (10) in the following years.7 After the discovery of penicillin and 
other antibiotics of natural origin, natural products were the main research focus of big 
pharmaceutical companies. 
The focus was not limited to anti-infective agents but also expanded to other pharmacological 
targets. In the 1970s, mevastatin (11) was isolated from the fungus Penicillium citrinum which led to 
the establishment of the statin group as an extremely effective antihyperlipidemic agents that work 
by inhibiting cholesterol biosynthesis and is still used today.11  
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During the 1980s about 62% of antineoplastic agents approved were natural products or related to 
natural products in some ways. In some cases, the original lead compound exhibited high toxicity 
profile and chemists had to modify parts of the structure to arrive at a more tolerated semi-synthetic 
compound that can be used as a drug.11 Good examples of effective natural products for the 
treatment of cancer are the vinca alkaloids, vinblastine (12) and vincristine (13). Simple 
modifications of these new alkaloids gave the synthetic analogue, vinorelbine (14), which was 
approved for use shortly after.11, 7   
 
 
 
                                                                
 
Before the beginning of the 1990s drug discovery was a serendipitous process where scientists 
usually used whole extracts or pure compounds and screened them for biological activity without 
thorough understanding of their molecular biological target (mechanism of action). This process was 
called phenotypic drug discovery or classical pharmacology.12, 13 
Recent advancement in the sequencing of the human genome led to a rapid cloning and synthesis of 
purified proteins. New techniques were developed to use the isolated synthesized protein targets. 
High-throughput screening where millions of compounds are tested on a specific protein target for 
receptor/ligand chemical interaction is practiced by big pharmaceutical companies. Candidates that 
show a promising affinity to a target are then modified for maximum affinity minimum toxic profile 
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and then tested in vivo on animal and then onto human clinical trials.12,11,14 This new approach is 
known as target based drug discovery or reverse pharmacology (Figure 1.1).12,14  
 
 
        Phenotypic drug discovery                                                                 Target based drug discovery 
 
Functional studies                                                                                                             Target identification       
                                                                                                 Protein synthesis 
 
                                                                                                    Interaction with protein                                            
                                                                                                                                                                                                                                         
 
Target identification                                                                                                      Functional studies 
 
 
Figure 1.1 - Comparison between classical and reverse pharmacology 
 
The new drug discovery approach however did not inhibit natural products research and the 
discovery of new lead compounds of natural origin. A study that examined all new approved drugs 
from 1981 to 2014 found that a total number of 1211 new drugs were approved worldwide, of 
which 320 drugs were natural products or their derivatives. That is 32.7% of all medicines approved 
for the past three decades (see Figure 1.2).15  
Molecular studies  In vivo/vitro assays 
Functional activity in vivo/vitro 
Biological/physiological change 
Lead compound 
Identification of a promising protein 
Molecules screened randomly  
Lead compound  
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Figure 1.2 – All approved medicines between 1981-2014  
 
The latest milestone in natural products drug discovery was the extraction and isolation of 
artemisinin (15), an extremely potent anti-malarial agent isolated from Artemisia annua by the 
Chinese scientist Tu Youyou. Artemisinin has become the lead compound in the development of new 
anti-malarial agents to overcome the multi-drug resistance strain and was subsequently modified to 
produce semi-synthetic analogues with higher potency. Tu Youyou was awarded half of the 2015 
Nobel Prize in Medicine. Artemisinin and its derivatives are now the first line treatment against 
Plasmodium falciparum malaria.16,17,18 
 
 
 
 
 
Natural product
Botanical
Natural product 
derivitave 
Synthetic
ALL APPROVED MEDICATIONS FROM 1981 TO 2014
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1.2 The Alkaloids 
1.2.1 General 
Alkaloids are a class of naturally occurring organic molecules produced by a variety of organisms 
including bacteria, fungi, plants and animals.19 The German pharmacist Carl Friedrich Wilhelm 
Meissner introduced the term ‘alkaloid’ in 1819. He defined it as “a substance derived from plants 
that react like alkalis”. However, this definition was regarded to be not sufficiently broad to 
encompass all substances that are readily perceived as alkaloids. Over the years the term ‘alkaloid’ 
was redefined many times and today the most widely accepted definition is “alkaloids are naturally 
occurring nitrogen-containing organic compounds which have a greater or lesser degree of basic 
character”.20, 21  
Alkaloids constitute one of the most diverse classes of secondary metabolites. They are 
biosynthesized by unique metabolic pathways involving amino acid precursors and show a broad 
spectrum of pharmacological activity.22 Secondary metabolites are molecules that are produced in 
minute amounts by a unique biosynthetic pathway in each specific organism, where in many 
instances genetic and enzymatic evidence have proven the proposed pathway.23 On the other hand, 
other natural molecules produced by these organisms such as carbohydrates and proteins are 
referred to as primary metabolites.22,23,24 There is an extreme variation in the structures of different 
alkaloids. A comparison between coniine (16) a plant toxin and batarachotoxin (17) produced by the 
golden poison frog can show the difference in structure complexity between alkaloids.25, 26   
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Due to the vast number of alkaloids that needs to be classified into meaningful and convenient 
groups, the most widely used classification of alkaloids is based on their nitrogen-containing 
structural features. Therefore, alkaloids are classified into five major groups (Table 1.1): 
 
1) Heterocyclic alkaloids  
2) Alkaloids with an exocyclic nitrogen atom  
3) Polyamine alkaloids 
4) Peptide alkaloids  
5) Terpene and steroidal alkaloids.20,21  
 
Table 1.1 – Selected examples of each group of alkaloids 
1- Heterocyclic alkaloids 
 
These are alkaloids that have nitrogen as part 
of their cyclic ring system. They are the most 
common group of alkaloids in nature. An 
example of heterocyclic alkaloids is cocaine 
(18).21 
 
 
 
2- Alkaloids with exocyclic nitrogen atom 
 
Also called proto alkaloids or biological amines, 
these alkaloids have nitrogen that is not part of 
any ring system. They are less common in 
nature. An example of this group is ephedrine 
(19). 21 
 
 
 
 
 
3- Polyamine alkaloids 
 
These are aliphatic molecules with one or more 
amino groups. An example of polyamines is 
putrescine (20).27 
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4- Peptide alkaloids  
 
Peptide alkaloids are composed of amino acid 
monomers linked by peptide bonds. 
An example of peptide alkaloids is ergotamine 
(21). 21 
 
 
 
 
 
 
 
5-Terpene and steroidal alkaloids 
Terpene alkaloids are made of a mono-, sesqui-, 
di-, and tri-terpenoid skeleton while steroidal 
alkaloids as the name indicates have a steroid 
skeleton. An example of steroidal alkaloid is 
solasodine (22). 21 
 
 
 
 
     
 
 
1.2.2 Occurrence and distribution  
Alkaloid occurrence in the plant kingdom is predominant in higher plants (angiosperms including 
both mono- and di-cotyledons). Alkaloids may be found in the flowers, fruits, leaves and seeds. 
However, there are some lower non-flowering plants that produce alkaloids, e.g., paclitaxel (23) 
from Taxus brevifolia. Some fungi are also known to produce alkaloids such as ergotamine (21).28 
Alkaloids are also produced by the animal kingdom. For example the toxic steroidal alkaloid 
samandarin (24) secreted by the fire frog Salamandra salamandra.29 Table 1.2 shows some selected 
examples of plants alkaloids.  
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Table 1.2 – Distribution of selected alkaloids in selected families within the plant kingdom.30 
Family Plant genus Alkaloid 
Amaryllidaceae Amaryllis Lycorine 
Galanthus, Narcissus Galanthamine 
Ancistroclaceae Ancistrocladus Michellamine B 
Apiaceae Conium Coniine 
Apocynaceae Alstonine Alstonia 
Rauvolfia Ajmalicine 
Rauvolfia Ajmaline 
Aspidosperma Anspidospermine 
Holarrhena Conessine 
Ochrosia Ellipticine 
Rauwolfia Reserpine 
Catharanthus 
 
Vinblastine 
Vincristine 
Yohimbe Yohimbine 
Arecaceae Areca  Arecoline 
Aristolochiaceae Aristolochia Aristolochic acid 
Asteraceae Senecio Senecionine 
Berberidaceae  Berberis Berberine 
Mahonia Berberine 
Boraginaceae Heliotropium Indicine N-oxide 
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Cactaceae Lophophora Mescaline 
Celastraceae  Catha Cathine  
Cathinone  
Chenopodiaceae Anabasis Anabasine 
Colchicaceae Colchicum Colchicine 
Convolvulaceae Calystegia  Calystegines  
Dioncophyllaceae Triphyophyllum Dioncophylline C  
Ephedraceae Ephedra Ephedrine  
Equisetaceae Equisetum  Palustrine  
Erythroxylaceae Coca Cocaine 
Fabaceae Castanospermum  Canstanospermine 
Anagyris Anagyrine 
Laburnum Cytisine 
Crotalaria Monocrotaline 
Physostigma Physostigmine 
Cytisus Sparteine 
Swainsona Swainsonine 
Fumariaceae Dicentra Chelerythrine 
Melanthiaceae Schoenocaulon Cevadine 
Veratrum Rubijervine 
Loganiaceae Strychnos Strychnine 
Lycopodiaceae Lycopodium Lycopodine 
Menispermaceae  Chondrodendron Tubocurarine 
Moraceae Morus  Calystegines 
Nyssaceae Camptotheca Camptothecin 
Orchidaceae Dendrobium Dendrobine 
Papaveraceae Papaver  
 
Morphine 
Codeine 
Papaverine 
Narcotine  
Peganaceae Peganum Harmaline 
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Ranunculaceae Aconitum Aconitine 
Delphinium Ajaconine 
Rubiaceae Coffea Caffeine 
Psychotria Emetine 
Cinchona  
 
Quinine 
Quinidine 
Rutaceae Acronychia Acronycine 
Zanthoxylum Canthine-6-one 
Pilocarpus Pilocarpine 
Solanaceae Capsicum  Capsaicin  
Atropa Scopolamine 
Datura 
Duboisia 
Hyoscyamus 
Mandragora Hyoscyamine 
Solanum Solanine 
Nicotiana Nicotine 
Sterculiaceae Theobroma Theobromine 
Taxaceae Taxus  Paclitaxel 
Baccatin III 
Theaceae Camellia Caffeine 
 
 
1.2.3 Properties of alkaloids 
Alkaloids are found in plants as solid colourless crystals or amorphous. They exist in plants in three 
different forms, i.e., free-state, acidic salts, or N-oxides. There are coloured alkaloids although it is 
less common, e.g., sanguinarine is copper-red alkaloid. Beside carbon and nitrogen atoms, most 
alkaloids have oxygen atom, and less commonly sulfur atoms.31 
Solubility is a crucial physical property for alkaloids used as medicines. Most alkaloid-based drugs are 
delivered in solution form. A simple modification from free-state to salt or vice-versa can affect the 
solubility of an alkaloid greatly.31 
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Alkaloid presence in plants can be tested by the use of Dragendorff’s reagent (potassium iodide-
bismuth nitrate) which when reacts with alkaloids gives an orange colour.  
 
 
1.2.4 Physiological importance of alkaloids in plants 
There are several hypotheses about the true physiological functions of alkaloids, some of which are 
presented below: 
1) end product of metabolic processes – they serve no function.32 
2) synthesized and used by plants as weapons and toxins to defend against predation 
3) as growth regulators 
4) as storage reservoir for nitrogen  
5) as substitutes for minerals in plants   
The first and fifth hypotheses are widely discredited now due to overwhelming evidence of the 
usefulness of alkaloids within the species that produce them.33 
 
1.2.5 Classifications of heterocyclic alkaloids 
Heterocyclic alkaloids are subdivided into fifteen distinct groups based on their heterocyclic ring 
system (Table 1.3).21 
 
Table 1.3 – Classification of alkaloids according to their C-N skeleton.21  
Class Description 
 
 
Pyrrolidine 
 
• Also known as 
tetrahydropyrrole  
• Is a cyclic secondary 
amine 
• Saturated heterocycle  
 
 
 
Piperidine  
 
• Mostly found in the 
genus Piper  
• Saturated heterocyclic 
secondary amine 
 14 
 
 
 
pyrrolizidine 
 
• Fusion of two 5-
membered rings  
 
 
Pyridine  
 
• Closely related to 
benzene with one 
methine replaced by a 
nitrogen atom 
 
 
 
Pyrazine 
 
• Symmetrical di-
substituted benzene 
ring  
   
 
 
Imidazole  
 
• A planar five-
membered ring. 
 
• Exist in two tautomeric 
forms  
 
 
 
Indole 
 
• Bicyclic alkaloids 
constituting fused 
benzene and pyrrole 
rings 
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Indolizidine  
 
• Bicyclic alkaloids with a 
six-membered ring 
fused to a five-
membered ring with 
one of the ring junction 
atoms being a nitrogen 
atom. 
 
 
Quinolizidine 
• Bicyclic alkaloids with 
two six-membered 
rings fused together 
with one of the ring 
junction atoms being a 
nitrogen atom. 
 
Purine  
• Fusion of pyrimidine 
and imidazole rings. 
 
 
 
 
Quinoline 
• Fusion of pyridine and 
benzene rings 
 
 
 
 
Isoquinoline 
• Isomer of quinoline   
 
 
 
 
 
 
Quinazoline  
• Fusion of benzene and 
pyrimidine rings. 
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Pteridine 
 
• Fusion of pyrimidine 
and pyrazine rings. 
 
 
Tropane 
 
• Class of bicyclic 
alkaloids with tropane 
ring. 
• Mostly found in the 
plant family of 
Solanaceae. 
 
 
 
1.2.6 Indolizidine alkaloids 
One of the fifteen groups of heterocyclic alkaloids is indolizidine alkaloids, which can be found in a 
myriad of species across the plant kingdom. They are also found on the skin of some amphibians, in 
ants, and microorganisms.34 However, many of these compounds are assigned under different 
classifications due to their biosynthetic origin or structural complexity that favours another 
heterocyclic classification.  Indolizidine alkaloids are found in a number of different plant families, 
i.e., Orchiaceae, Asclepidaceae, Moraceae and Convolvulaceae. This research will focus on two sub-
classes of indolizidine alkaloids, namely, phenanthroindolizidine and the less common 
benzopyrroloisoquinoline, which were isolated from Asclepidaceae and Moraceae (see Figure 1.3).35   
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                                           Indolizidine                                                  Benzene                                Pyrrolidine                 
                                                   
 
         Phenanthrene                                                                                               Isoquinoline  
 
 
Figure 1.3 - The phenanthroindolizidine and benzopyrroloisoquinoline (naphthaloindolizidine) 
skeletons 
 
 
1.3 Phenanthroindolizidine Alkaloids 
1.3.1 - General 
Phenanthroindolizidine alkaloids are a subgroup of indolizidine alkaloids. As the name indicates 
phenanthroindolizidines are a group of organic molecules where a phenanthrene ring system is 
fused with an indolizidine moiety. The first phenanthroindolizidine to be discovered was tylophorine 
(28) isolated from Tylophora asthmatica. Phenanthroindolizidines attracted much attention from 
scientists in the 1960s with their extremely potent anti-tumor, anti-inflammatory, anti-viral and 
ameobicidal activities.36 Nonetheless, there were few drawbacks for their use as potential 
therapeutic agents such as low availability in nature, CNS toxicity and low in vivo anticancer 
toxicity.37 These major drawbacks however did not stop the interest in phenanthroindolizidines and 
their unique chemistry and bioactivity. A large number of studies were carried out later and Table 
1.4 lists all the phenanthroindolizidine alkaloids discovered until the present day.  
 
 18 
 
 
 
Table 1.4 – A list of all naturally occurring phenanthroindolizidine alkaloids isolated to date.  
Plant Alkaloid Structure Reference 
Albizzia julibrissin  Antofine  25 36 
 
Antitoxicum 
funebre 
Antofine 25 35 
 
Cynanchum 
komarovii 
Antofine 25 36 
 14-Hydroxyantofine 26 36 
 7-Demethoxytylophorine N-oxide 27 38 
 
Cynanchum 
vincetoxicum 
Antofine 25 39 
 Tylophorine 28 35 
 (-)-10β-Antofine N-oxide 29 40 
 (-)-10β,13aα-14β-Hydroxyantofine N-
oxide 
30 40 
 (-)-10β,13aα-Secoantofine N-oxide 31 40 
 (-)-(R)-13aα-6-O-Desmethylantofine 32 41 
 Secoantofine 33 41 
 (-)-(R)-13aα-6-O-Desmethylsecoantofine 34 41 
 
Ficus fistulosa Tylophorine 28 42 
 19 
 
 Antofine 25 43 
 14-Hydroxyantofine 26 42 
 Secoantofine 33 42 
 Tylocrebrine 35 42 
 Septicine  36 42 
 Fistulopsine A 37 42 
 Fistulopsine B 38 42 
 3,6-Didemethylisotylocrebrine 39 42 
 
Ficus hispida O-Methyltylophorinidine 40 44 
 Hispiloscine 41 45 
 
Ficus septica Antofine 25 46, 47 
 Tylophorine 28 46 
 Tylocrebrine 35 46 
 Dehydrotylophorine 42 35 
 Isotylocrebrine 43 46 
 Septicine 36 46 
 10R,13aR-Tylophorine N-oxide 44 47 
 10R,13aR-Tylocrebrine N-oxide 45 47 
 10S,13aR-Tylocrebrine N-oxide 46 47 
 10S,13aR-Isotylocrebrine N-oxide 47 47 
 10S,13aS-Isotylocrebrine N-oxide 48 47 
 Ficuseptine A 49 48 
 20 
 
 Ficuseptine B 50 47 
 Ficuseptine C 51 47 
 Ficuseptine D 52 47 
 Ficuseptine E 53 49 
 Ficuseptine F 54 49 
 Ficuseptine G 55 49 
 Ficuseptine H 56 49 
 Ficuseptine I 57 49 
 Ficuseptine J 58 49 
 Ficuseptine K 59 49 
 Ficuseptine L 60 49 
 Ficuseptine M 61 49 
 Ficuseptine N 62 49 
 14-Hydroxyisocrebrine N-oxide 63 46 
 14-Hydroxy-3,4,6,7-
tetramethoxypheanthroindolizidine 
64 46 
 14-Hydroxy-2,3,4,6,7-
pentamethoxyphenanthroindolizidine 
65 46 
 
Hypoestes 
verticillaris 
Hypoestestatin 1 66 36 
 Hypoestestatin 2 67 36 
 
Pergularia pallida Tylophorine 28 35 
 Tylophorinidine 68 35 
 21 
 
 Tylophorinine 69 35 
 Deoxytylophorinine 70 35 
 14-Hydroxytylophorine 71 35 
 
Typhlora 
asthmatica 
Tylophorine 28 39 
 Tylophorinidine 68 39 
 O-Methyltylophorinidine 40 39 
 Tylophorinine 69 39 
 Isotylocrebrine 43 39 
 Deoxytylophorinine 70 39 
 Desoxytylophorinidine 72 39 
 
Tylophora 
atrofolliculata 
Tylophorinidine 68 50 
 Tylophorinine 69 50 
 Tylophoridicine C 73 50 
 Tylophoridicine D 74 50 
 Tylophoridicine E 75 50 
 Tylophoridicine F 76 50 
 11-Ketotylophorinidine 77 51 
 13aS-2,6-Didemethyltylophorine 78 51 
 2-Hydroxyltylophorinidine 79 51 
 10R-3-O-Demethyltylophorinidine N-
oxide 
80 51 
 10R-2-Hydroxyltylophorinine N-oxide 81 51 
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 10R-2-Methyl-O-methyltylophorindine 
N-oxide 
82 51 
 10R,13aS-Tylophorine N-oxide  83 51 
 10R-Deoxytylophorinine N-oxide 84 51 
 10S-2-Hydroxyl-6-
demethyltylophorinine N-oxide 
85 51 
 13aR-2-Hydroxyltylophorinine 86 51 
 11-keto-O-methyltylophorinidine 87 51 
 3-O-demethyltylophorinidine 88 51 
 
Tylophora hirsuta Isotylocrebrine  43 36 
 Tylophorine 28 36 
 14-Hydroxyisotylocrebrine 89 36 
 4-Demethylisotylocrebrine 90 36 
 Tylohirsutinine 91 36 
 Tylohirsutinidine 92 36 
 13a-Methyhylohirsutine 93 36 
 13a-Methyltylohirsutinidine 94 36 
 13a-Tydroxysepticine 95 36 
 14-Desoxy-13a-methyltylohirsutinidine 96 36 
 5-Hydroxy-O-methyltylophorinidine 97 36 
 Tylohirsuticine 98 36 
 13a-Hydroxytylophorine 99 36 
 
Tylophora indica Tylophorine 28 36 
 Tylophorinidine 68 36 
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 Tylophorinine 69 36 
 Septicine 36 36 
 Isotylocrebrine 43 36 
 3-O-Demethyltylophorinidine 88 36 
 4-Demethyltylophorine 90 36 
 6-Demethyltylophorine 100 36 
 5-Hydroxy-O-methyltylophorinidine 97 36 
 Tyloindicine A 101 36 
 Tyloindicine B 102 36 
 Tyloindicine C 103 36 
 Tyloindicine D 104 36 
 Tyloindicine E 105 36 
 Tyloindicine F 106 36 
 Tyloindicine G  107 36 
 Tyloindicine H  108 36 
 Tyloindicine I  109 36 
 Tyloindicine J 110 36 
 4,6-Desdimethylisotylocrebrine 111 36 
 14-Hydroxyisotylocrebrine 89 36 
 
Tylophora ovata Tylophorine 28 52 
 O-Methyltylophorinidine 40 52 
 Septicine 36 52 
 6-Desmethyltylophorine 100 52 
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 Tylophovatine A 112 50 
 Tylophovatine B 113 50 
 Tylophovatine C 114 50 
 
Tylophora 
tanakae 
Tylophorine 28 53 
 Isotylocrebrine 43 53 
 6-Demethyltylocrebrine     115 53 
 3-Demethylisotylocrebrine  116 53 
 3-Demethyl-14-hydroxyisotylocrebrin 117 53 
 Isotylocrebrine N-Oxide  118 53 
 14-Hydroxyisotylocrebrine N-Oxide 119 53 
 3-Demethyl-14-Hydroxyisotylocrebrine 
N-Oxide  
120 53 
 Tylohorinine N-Oxide  121 53 
 7-Demethyltylophorine  122 53 
 Tylophorine N-Oxide  83 36 
 7-Demethyltylophorine N-Oxide  123 36 
 3,6-Diemethylisotylocrebrine  124 36 
 14-Hydroxy-3,6-
didemethylisotylocrebrine 
125 36 
 
Vincetoxiucm 
hirundinaria 
(+)-Antofine N-oxide 29 36 
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 (-)-Antofine N-oxide 
 
126 36 
 
Vincetoxicum 
officinale 
Tylophorine 28 35 
 Antofine 25 35 
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1.3.2 Biosynthesis of Phenanthroindolizidine Alkaloids  
 
In 1984 a study was carried out to determine the biosynthetic pathway of phenanthroindolizidines. 
Phenylalanine and tyrosine were known to be the amino acid precursors to tylophorine and 
tylophorinidine, while ornithine is the amino acid that is responsible in providing the nitrogen-
containing pyrrole ring in the indolizidine structure.54  
To allow the elucidation of the biosynthetic pathway, radiolabelled 2-pyrrolidin-2-ylacetophenone 
and its oxygenated derivatives were used. The compounds were labelled with 14C and 3H 
radioisotopes that can be traced. The results of the study allowed the partial elucidation of the 
biosynthetic pathways to produce phenanthroindolizidine alkaloids (Figure 1.4).54,55 
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Figure 1.4 – Partial biosynthetic pathway to phenanthroindolizidines.54 
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1.3.3 Biological activity of phenanthroindolizidine alkaloids  
The biological activities of phenanthroindolizidine alkaloids were studied extensively and they were 
found to possess tremendous anti-tumor, anti-viral, and anti-inflammatory activities. Initially the 
crude extract from T. indica was subjected to numerous biological tests, and it showed promising 
anti-inflammatory, immunosuppressive and cytotoxic activities. Due to its immense 
immunosuppressive activity, T. indica crude extract was later subjected to clinical studies for the 
treatment of asthma and showed noticeable efficacy over placebo. The immunosuppressive effect of 
the extract was attributed to an increase in the secretion of adrenal corticosteroids. Tylophora indica 
extract is currently marketed as a supplement in products such as T. Asthmatica plus®.56 
Investigation of the pure alkaloids from T. indica was then carried out with specific focus on 
tylophorine, due to its relatively high abundance in the plant (0.015-0.035%) and ease of synthesis. 
Since the plant extract showed prominent anti-inflammatory, cytotoxicity and immunosuppression 
the pure alkaloids from the plant were expected to carry the same effect. 
 
In vitro cytotoxicity assessment showed that phenanthroindolizidines possess remarkable 
cytotoxicity, established by a study carried out in 1997 by the NCI. The compounds used in this study 
inhibited the growth of all 60-cell lines used by the NCI in the low nanomolar range.57 As can be seen 
in Table 1.5, phenanthroindolizidine alkaloids showed very little selectivity between the tested cell 
lines. For example, paclitaxel which was tested in the same study showed an IC50 range between 2-
1000 nM, showing almost a 500-fold difference. Moreover, the compounds retained almost the 
same level of potency against the multi-drug resistant cancer cells. Phenanthroindolizidine alkaloids 
were studied thoroughly as potential anti-cancer lead compounds after the outcome of this study. 
 
Table 1.5 - In vitro cytotoxicity of some phenanthroindolizidine alkaloids.57   
Compound  60-cell line panel GI50 (nM) Individual cell line GI50 (nM) 
Mean Range A-549 MCF-7 HCT-116 
Tylocrebrine (35) 29.5 10-126 25 50 25 
Tylophorine (28) 17.5 10-400 10 10 10 
Antofine (25) ND ND 10.4 12.4 9.9 
Tylophorinine (69) 57.6 10-500 63 63 40 
Tyloindicine F (106) 0.1 0.1-1 0.1 0.1 0.1 
A549 = non-small cell lung carcinoma, MCF-7 = breast carcinoma, HCT 116 = colon carcinoma, ND = 
No data. 
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In vivo studies showed disappointing results as most phenanthroindolizidines tested were virtually 
inactive against sarcoma 180, adenocarcinoma 755, B16 melanoma, Lewis lung, P1534 leukemia and 
Walker 256 carcinosarcoma animal models. However, tylocrebrine (35) showed promising activity 
against lymphoid leukemia L1210 mouse models with 155% life extension at a dose of 20 mg/kg. This 
justified its entry into clinical trials for leukemia in 1965. Nevertheless, due to severe CNS toxicity 
and side effects, namely, ataxia and disorientation, the trials were aborted before the establishment 
of tylocrebrine’s therapeutic value in humans. Until this day tylocrebrine is the only 
phenanthroindolizidine to have entered clinical trials.56 
 
 1.3.4 Mechanism of action of phenanthroindolizidine cytotoxicity 
Studies have shown that phenanthroindolizidine alkaloids interact with multiple targets in the tumor 
cell. It is possible however that the cytotoxicity of these alkaloids is caused by a combination of drug-
target interactions.   
1) Protein, DNA and RNA biosynthesis inhibition 
It is by far the most extensively studied mechanism of action for phenanthroindolizidine anti-
cancer activity. Tylophorine and tylocrebrine were found to inhibit the biosynthesis of proteins in 
Ehrlich ascites-tumor cells while exerting no effect on RNA synthesis.58 In addition, antofine has 
been reported to inhibit protein biosynthesis as well.59 since the compounds exerted no similar 
effect on E. coli (bacterial prokaryotic 70s ribosomes) they were hypothesized to specifically 
target the eukaryotic 80s ribosomes protein biosynthesis.58 On the other hand, tylocrebrine was 
shown to inhibit DNA synthesis in HeLa cells. It is worth mentioning that DNA and protein 
synthesis pathways are interdependent, consequently, protein synthesis inhibitors will in turn 
inhibit DNA synthesis as well. Thus indicating that inhibition of DNA synthesis is caused primarily 
by ribosomal inhibition.56  
2) Apoptosis and cycle arrest  
Compounds that inhibit protein synthesis will prevent proliferation, thus they are rather 
cytostatic. Although cytostatic agents can treat malignancies by stopping the accelerated 
proliferation in neoplastic growth, cancer cell death (apoptosis) is needed in order to achieve 
complete remission. T. indica extract was shown to completely inhibit cell multiplication at 
concentration of 0.1 M. Interestingly, increasing the dose by ten-fold showed prominent 
apoptosis, however this can be attributed to synergistic effect, and the concentration is too high 
to be therapeutically practicable. Pure phenanthroindolizidines were tested and showed no 
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significant apoptosis indicating that phenanthroindolizidines are in fact cytostatic, with G1-Phase 
arrest linked to suppression of cyclin A2 expression. 56, 60  
3) Angiogenesis  
 
Tumor cells have a very high oxygen demand for their basic sustenance, this demand is met 
by angiogenesis (the formation of new blood vessels) which is triggered by the release of 
VEGF growth factor and HIF-1. Targeting angiogenesis is an effective way to suppress tumor 
growth. Studies shows that phenanthroindolizidine alkaloids are potent inhibitors of HIF-1 
and VEGF at low nanomolar concentrations.61 
 
4) Cell differentiation  
Due to their prominent effect as protein synthesis inhibitors it is not surprising that 
phenanthroindolizidines induce phenotypic changes in transformed cells. Tylophorine’s 
effect on cell differentiation was investigated by monitoring the expression of two tumor 
biomarkers, albumin and alpha-fetoprotein (AFP). Tylophorine (1 M) resulted in a 
suppression of AFP and an increase in albumin expression which is consistent with cell 
differentiation.60 
 
5) Other molecular targets 
Other targets have been proposed for the cytotoxicity of phenanthroindolizidine. 
Thymidylate synthase62 and dihydrofolate reductase63 have been observed at high 
concentrations (>30 M) of tylophorinidine. However, it seems quite unjustifiable to explore 
these effects further since phenanthroindolizidines exert their effect at the nanomolar 
range.   
 
 
1.3.5 Other biological activities of phenanthroindolizidines  
As mentioned above, T. indica crude extract showed anti-inflammatory activity in vitro and in vivo 
(animal and human models). The activity of pure alkaloids as anti-inflammatory agents was then 
investigated. This was demonstrated in several studies that confirmed tylophorine anti-inflammatory  
effects  in vitro and in vivo.64, 65 It was shown that tylophorine significantly decreased the production 
of TNF, iNOS and COX-2 at 3-10 Mwithout causing NF-B inhibition.56,64 Antiviral activity of 
phenanthroindolizidines have also been reported with antofine showing prominent anti-TMV activity 
in the nanomolar range.56 
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1.4 Benzopyrroloisoquinoline Alkaloids 
1.4.1 – General 
Benzopyrroloisoquinoline or naphthaloindolizidine alkaloids are very closely related to the 
phenanthroindolizidine alkaloids in terms of structure. However, they are far less common with only 
three benzopyrroloisoquinolines isolated from natural origin to date and in this research the fourth 
compound of this class is being reported. The three known benzopyrroloisoquinolines previously 
isolated are: 
 
1. Vincetene (127)  
Vincetene was isolated from from Cynanchum vincetoxicum. Cynachum is a genus of about 
300 species that belongs to the Apocynacaea family. The full NMR data was not provided in 
the paper published by the authors, instead they mentioned key proton signals only and the 
stereochemistry at C-11a stereocentre was not established.66 
 
 
 
 
 
 
2. 2,3-Dimethoxy-6-[3-oxobutyl]-7,9,10,11,11a,12- hexahydrobenzo [f]pyrrolo[1,2-b] 
isoquinoline (128)  
 
Alkaloid 128 was isolated from another Cynanchum species C. komarovii. 1H NMR data were 
fully reported. However, the stereochemistry of 128 was also not determined due to 1H 
NMR signals involving H-11a and other hydrogens overlapped.38 
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3.   ()-Fistulosine (129) 
Fistulosine was isolated from the leaves of F. fistulosa Reniw. ex Blume. 1H and 13C NMR data 
were reported and the specific optical rotaion of 129 was reported as [α]D -11 (c 0.08, 
MeOH). Relative stereochemistry of 129 was not established by NMR data due to signal 
overlapping involving H-11a. Nevertheless, ()-fistulosine (129) was isolated together with 
three known phnanthroindolizidines all of which had negative optical rotation and R 
stereochemistry at the indolizidine ring junction carbon. ()-Fistulosine (129) was thus 
assigned R at C-11a  by anology.43  
 
  
1.4.2 – Biological activity of benzopyrroloisoquinoline alkaloids 
A study was performed to assess the cytotoxicity of synthetic benzopyrroloisoquinoline analogues of 
antofine and tylophorine. They however showed no apparent cytotoxicity.67 Fistulosine (129) was 
previously tested for antifungal activity and it showed no activity.43 Fistulosine isolated in the 
present study was tested for cytotoxic activity and was also found to be inactive. Nonetheless, the 
other natural benzopyrroloisoquinoline alkaloid (128) showed very modest activity against tobacco 
mosaic virus with 15% growth inhibition at 500g/mL. 
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1.5 The Genus Ficus 
1.5.1 General 
Ficus, commonly known as figs, is a pantropical genus of trees, vines and shrubs most of which are 
evergreen. Ficus is a massively diverse genus with over 800 species worldwide (Table 1.7). It is the 
largest of the 40 genera that make up the Moraceae family. Moraceae is divided into five tribes, 
specifically, Artocarpeae, Castilleae, Dorstenieae, Ficeae (which Ficus is part of) and Moreae.68 Ficus 
is widely distributed around Peninsular Malaysia with about 99 species.69 
 
Table 1.7 – Global distribution of the genus Ficus.68 
Region Number of subgenera Number of species 
Indo-Pacific 6 >500 
Borneo 6 >160 
Papua New Guinea 6 >150 
Afrotropics 5 112 
Neotropics 2 132 
Global 7 >800 
 
Ficus have a diverse range of botanical characteristics, many of which are common for tropical 
rainforest ecosystem such as hemi-epiphytes (including strangling figs and banyans), large woody 
climbers (e.g., Ficus pumila) and cauliflorous trees (e.g., Ficus fistulosa Rienw ex Blume). Figs support 
an astonishing 1200 species of vertebrate globally, some of which feed exclusively on figs.68 
 
Figs have a distinctive and highly specific system for pollination. It depends to a great extent on 
specific wasps, namely, Agaoninae, Agaonidae and Chalcidoidae. Pregnant female wasps enter the 
fig fruit through a tiny hole in the bottom, which is highly selective and only allows the exact species 
of wasps that pollinates it to enter. The wasp loses its wings in the process of gaining entrance. The 
wasp pollinates the plant by brushing against uniovular female flowers with pollens it carries. 
Concurrently, the wasp lays its eggs on other ovules and then dies within the fig. Ovules with eggs 
laid within them are then triggered to form a gall; later on, the wasp larvae grow. After the wasp has 
fully grown within the gall it erupts and exits the fig. Simultaneously, the wasp gathers pollen from 
male flowers which have developed at the same time of the wasp to benefit from the egress of the 
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wasp. Once the wasp breaks free of the fig, the fig develops into a fruit. When female wasps leave 
the fig they have a limited time (hours to 2-3 days) to find a receptive fig fruit.68,70 
 
Studies have shown that Ficus species have been cultivated for 11,000 years. Different species of figs 
were grown and used as a food source. Chinese and Indian traditional medicines are known to use 
Ficus for medicinal purposes. However, the use of Ficus was originally derived in the Middle East and 
are mostly found there.71 
 
Recent studies on the biological activity of alkaloids from Ficus involved the isolation of pure 
compounds and assessing their biological activities for potential therapeutic uses. Ficus carica 
produces fig latex that was found to inhibit the growth of sarcoma in vivo (albino rats). Antofine (25), 
(+)-isotylocrebrine (43) and tylophorine (28) isolated from Ficus septica, showed potent cytotoxic 
activity against several tumour cell lines in vitro with GI50 values of 2 μM. Fistulopsines A (37) and B 
(38) isolated from the leaves of Ficus fistulosa exhibited in vitro cytotoxicity against HCT 116 and 
MCF 7 cell lines with GI50 ranging between 2-7 μM. Hispidacine (130) showed an appreciable 
vasorelaxant activity in rat isolated aorta with concentrations just above 1 μM.42,45,48  
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1.5.2 – Previous investigation of the genus Ficus   
Ficus is one of the most under-investigated genera with only three species of Ficus reported the 
presence of alkaloids to the present day, namely, Ficus hispida, Ficus fistulosa and Ficus septica. 
Phenanthroindolizidine alkaloids make up the majority of the alkaloids isolated from the three Ficus 
species. They were found mainly in the leaves and bark of the investigated plants. Table 1.8 lists the 
alkaloids extracted from Ficus to date.  
 
 Table 1.8 – Alkaloids from F. fistulosa, F. hispida and F. septica. 
Species Source Alkaloid Name  Structure Reference 
F. 
fistulosa 
Bark 
and 
leaves 
Antofine 25 43 
()-Fistulosine 129 43 
Fistulopsine A 37 42 
Fistulopsine B 38 42 
14β-Hydroxyantofine 26 43 
Secoantofine 33 43 
(–)-3,6-Didemethylisotylocrebrine 39 42 
Septicine 36 42 
Tylophorine 28 42 
Tylocrebrine 35 42 
     
F. 
hispida 
Bark 
and 
leaves 
O-Methyltylophorinidine 40 45 
Hispiloscine  41 45 
Hispidacine  130 45 
 
F. 
septica 
Leaf Tylophorine 28 46 
Isotylocrebrine 43 46 
Antofine 25 46 
Tylocrebrine 35 46 
14α-Hydroxyisocrebine N-oxide 63 46 
Septicine 36 46 
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Secoantofine 33 46 
14-Hydroxy-3,4,6,7-
tetramethoxypheanthroindolizidine 
64 46 
14-Hydroxy-2,3,4,6,7-
pentamethoxyphenanthroindolizidine 
65 46 
Tylophorine N-oxide  83 46 
Norruspoline 131 46 
Phyllosterone 132 46 
Ficuseptamine A 133 46 
Ficuseptamine B 134 46 
Ficuseptamine C 135 46 
Bark Tylophorine 28 47 
Tylocrebrine 35 47 
Isotylocrebrine 43 47 
Antofine N-oxide 29 47 
Ficuseptine A 49 48 
Ficuseptine B 50 47 
Ficuseptine C 51 47 
Ficuseptine D 52 47 
10S,13aR-Tylocrebrine N-oxide 46 47 
10R,13aR-Tylocrebrine N-oxide 45 47 
10R,13aR-Tylophorine N-oxide 44 47 
10S,13aR-Isotylocrebrine N-oxide 47 47 
 10S,13aS-Isotylocrebrine N-oxide 48 47 
Root Ficuseptine E 53 49 
Ficuseptine F 54 49 
Ficuseptine G 55 49 
Ficuseptine H 56 49 
Ficuseptine I 57 49 
Ficuseptine J 58 49 
Ficuseptine K 59 49 
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Ficuseptine L 60 49 
Ficuseptine M 61 49 
Ficuseptine N 62 49 
 
 
  
 
 
 
1.6.3 – Ficus fistulosa Reinw. ex Blume  
 
F. fistulosa is an evergreen dioecious tree that can grow up to 10 m tall. It is distributed across India, 
South China, Taiwan and Malesia. F. fistulosa grows wildly in the forest at high altitudes up to 2000 
m. The species is very variable in terms of morphology and position of the figs and thus it is further 
subdivided into at least 6 variations.69 The focus of the present study was on F. fistulosa var. 
tengerensis (Miq.) Kuntze a variety of F. fistulosa found in Malesia.  
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1.6.4 Ficus fistulosa var. tengerensis (Miq.) Kuntze 
The term tengerensis was first coined by the Dutch botanist Friedrich Anton Wilhelm Miquel in 1867 
and it was assigned to a Ficus species (Ficus tengerensis Miq.).72 In 1965, Ficus tengerensis was 
reduced to a variety under the species Ficus fistulosa Reinw. ex Blume. to become Ficus fistulosa var. 
tengerensis73 and it was continued to be the accepted taxonomy of the species by later researchers 
such as Kochummen (1978). Berg and Corner in 2005 reclassified Ficus fistulosa var. tengerensis as a 
synonym to Ficus fistulosa without giving any further explanation.69 However, in 2011 Berg published 
a paper titled “Corrective notes on the Malesian members of the genus Ficus (Moraceae)” in which 
he described both Ficus fistulosa and Ficus fistulosa var. tengerensis as two distinct varieties and 
gave a detailed description of the two plants.74  
F. fistulosa var. tengerensis (Figure 1.6) is a small-leaved, ramiflorous (plants that have their fruits 
and flowers grow on branches and twigs) and evergreen tree. It is widely spread across the Malay 
Peninsula, Thailand, Sumatra, Java and Borneo. The tree can grow up to 20 m tall, and usually found 
on high altitudes up to 2000 m above sea level.74 
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Figure 1.6 – A) Foliage of Ficus fistulosa var. tengerensis. B) A close up of the fruit hanging from 
branches. C) A close up of the leaves with a hand to show relative size.  
 
On the other hand, the other variety F. fistulosa is a large-leaved, cauliflorous (fruits and flowers 
grow on the main tree trunk) plant. It is distributed widely across South East Asia as well as mainland 
China, India, and Bangladesh. F. fistulosa is found on altitudes as high as 1700 m above sea level.74  
 
 
 
 
 
 
 
 
 
A B
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Figure 1.7 – A) Fruits growing from the trunk of Ficus fistulosa. B) Profile shot of a leaf from Ficus 
fistulosa showing its shape and size.  
 
 
The leaves and bark of F. fistulosa collected in Malaysia were previously investigated and resulted in 
the isolation of two new septicine-type alkaloids (i.e., fistulopsines A (37) and B (38)) and four known 
phenanthroindolizidine alkaloids, namely, septicine (36), tylophorine (28), tylocrebrine (35), and 3,6-
didemethylisotylocrebrine (39).42 However, an earlier investigation of F. fistulosa by Subramaniam et 
al. (2009) reported the isolation of a benzopyrroloisoquinoline alkaloid (i.e., ()-fistulosine (129)) and 
three known phenanthroindolizidine and septicine-type alkaloids, namely, antofine (25), 14-
hydroxyantofine (26), and secoantofine (33).43  
 
The previous investigation of F. fistulosa showed the potential of this un-investigated species to 
produce novel biologically active alkaloids. Thus, the closely related variety F. fistulosa var. 
tengerensis was chosen to be the focus of this study after a preliminary biological screening deemed 
the crude extract to possess cytotoxic activity. A large scale extraction was then performed with the 
intent of extensive chemical investigation of the alkaloidal content of the plant.  
 
 
 
 
 
 
A
 B
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1.6 Research Objectives         
The primary aim of the present research is to investigate the alkaloidal composition and biological 
activity of the alkaloids obtained from the leaves of F. fistulosa var. tengerensis, which was not 
previously investigated and was found to contain alkaloids. However, alkaloids were not detected in 
the bark material.  The specific objectives of the present investigation are listed below:  
 
• To extract the dried-ground leaf material with 95% ethanol and obtain crude alkaloid 
mixture from the bulk ethanolic extract using an acid-base method. 
• To fractionate the crude alkaloid mixture into less complicated fractions using 
chromatography, and to isolate and purify alkaloids from semi-purified fractions using 
chromatography.  
• To characterize and determine the structures of the pure compounds isolated via 
spectroscopic data analysis. 
• To assess the biological activity of selected pure alkaloids in vitro. 
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Chapter Two 
 
Results and Discussion 
2.1 Overview  
Investigation of the alkaloid content of F. fistulosa var. tengerensis leaves has provided five pure 
alkaloids. ()-Tengerensine (1) and ()-tengechlorenine (2) were obtained as novel alkaloids, while 
()-fistulosine (3), (+)-antofine (4) and ()-seco-antofine (5) were known alkaloids. The dried leaves 
(15 Kg) were collected, extracted and eventually yielded 10.45g crude alkaloid mixture following the 
acid-base treatment. The yields of the alkaloids obtained from F. fistulosa var. tengerensis are shown 
in Table 2.1. 
Table 2.1 – Alkaloid contents of F. fistulosa var. tengerensis 
Alkaloid Yield (mg/kg-1) 
(±)-Tengerensine (1) 1.44 
(±)-Tengechlorenine (2) 0.80 
()-Fistulosine (3) 1.25 
(S)-(+)-Antofine (4)  0.14 
(R)-(-)-Secoantofine (5) 1.22 
 
 
 51 
 
During the isolation process of alkaloids from F. fistulosa var. tengerensis, chloroform was used as an 
eluting solvent for the fractionation of the main alkaloidal crude extract using vacuum column 
chromatography. The use of chloroform might have caused degradation of some alkaloids in the 
collected fractions. Phenanthroindolizidine alkaloids are extremely sensitive to light when they are in 
chloroform solution, due to the formation of isoquinolinum salts that can be recognised by their 
yellow appearance (Figure 2.1).75  
 
 
Figure 2.1 – The degradation of phenanthroindolizidines in CHCl3 solution. 
 
The isoquinolinuim salts of phenanthroindolizidines are highly stable under normal sample handling 
conditions. The reversal of the achiral isoquinolinium salt to give a racemic mixture of antofine for 
instance requires a very strong reducing agent such as, sodium borohydride, thus eliminating the 
possibility of artefact formation, due to chloroform use.39 On the other hand, the highly polar 
isoquinolinium salts of phenanthroindolizidine affected the isolation process, with many fractions 
becoming too polar to be separated on the silica using normal phase chromatography. This effect 
was most prominent when performing TLC on those fractions where the salts showed virtually no 
separation and no movement on the normal phase silica even with highly polar mobile phase. 
Another effect could be attributed to the isoquinolinium salts is the extreme ‘tailing’ effect that 
could not be overcome with the addition of ammonia.  
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2.2 Structure Elucidation  
2.2.1 Tengerensine (1) 
Tengerensine (1) was obtained as light yellowish needles, [α]D -0.7 (c 0.30, CHCl3). The UV spectrum 
showed characteristic phenanthrene maxima at 239.0 and 331.8 nm (log  4.70 and 4.04 
respectively). The IR spectrum showed a peak at 1702.2 cm-1, which is characteristic of ketone 
function. HRESIMS measurements yielded the molecular formula C44H50N2O6 (21 degrees of 
unsaturation) with a protonated ion peak detected at m/z 703.37580 corresponding to 
(C44H50N2O6+H+) (see appendix A). 
The 13C NMR spectrum (Table 2.2) accounted for 39 carbon signals out of the 44 determined by 
HRESIMS, indicating that five signals are overlapping. 13C NMR data together with HSQC established 
the carbons in the structure as follows, six methyls, ten methylenes, six aliphatic methines, six 
aromatic methines, four oxygenated aromatic carbons, ten quaternary carbons and two carbonyls. 
The 13C NMR spectrum suggested tengerensine to be a dimeric compound as most signals appearing 
in pairs.  
The 1H NMR spectrum (Table 2.2) showed the presence of six aromatic singlets ( 6.55, 6.94, 6.95, 
6.96, 7.04 and 7.51) suggesting the aromatic rings are substituted and fused together 
(naphthalenyl). This was also confirmed by the presence of 20 aromatic carbon signals indicating the 
presence of two naphthalenyl moieties. Furthermore, four distinct proton signals were observed as 
triplets at  4.02, 4.37, 4.54 and 4.84, an observation suggesting the presence of a tetra-substituted 
cyclobutane ring. The suggestion was verified by COSY and HSQC correlations. In addition, six methyl 
singlets were observed in the 1H NMR spectrum, four of which are characteristic of O-methyl singlets 
at 3.76, 3.91, 3.94 and 3.98. The other two methyl singlets at  1.65 and 2.31 were assigned to the 
acetyl groups from the observed HMBC 3J correlations with the two carbonyls at C 206.27 and  
207.82, respectively. 
 
Figure 2.2 – Gross structure of tengerensine (1)  
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Table 2.2 – 1H, 13C NMR and HMBC data of tengerensine (1) 
Position 1H  13C HMBC 
2J                                              3J 
1 6.96 s 101.51 C-2                                         C-3, C-4a 
2 - 149.36                    
3 - 148.59  
4 6.55 s 106.98                                                 C-5, C-2, C-12b        
4a - 128.98c   
5 6.94 s 124.84                                                 C-4, C-13 
6 - 129.26  
6a - 126.94c  
7 3.47 m 55.51a                                                 C-11a 
 4.37 d (13.7)   
9 2.33 m 55.51a C-10                                       C-11, C-11a 
 3.43 m     
10 1.82 md 21.55 C-11                                       C-11a 
 1.92 md   
11 1.70 m 31.14 C-10                                       C-12 
 2.19 m   
11a 2.16 m 60.05 C-12                                       C-10 
12 2.74 m 33.51 C-11a                                     C-11 
 3.16 dd (15, 2)    
12a - 128.67c  
12b - 126.53  
13 4.54 t (10) 39.42                                                C-5, C-14’, C-15 
14 4.02 t (10) 50.60 C-14’                                      C-6, C-15’ 
15 - 206.27  
16 (CH3) 1.65 s 28.43 C-15                                       C-14 
2-OMe 3.94 s 55.69b                                                C-2 
3-OMe 3.76 s 55.75b                                                C-3 
1’ 6.96 s 101.85 C-12b’                                    C-3’ 
2’ - 149.19  
3’ - 148.79  
4’ 7.04 s  106.73                                                C-2’, C-5’, C-12b’ 
4a’ - 129.67c  
5’ 7.51 s 123.02                                                C-4’, C-13’ 
6’ - 130.87  
6a’ - 127.38c  
7’ 2.75 d (14.5) 53.70                                                C-11a’ 
 4.16 d (14.5)   
9’ 2.16 m 55.16a                                                C-11’, C-11a’ 
 3.34 m   
10’ 1.95 md 21.55 C-11’ 
 2.04 md   
11’ 1.58 m 31.14                                                C-9’, C-12’ 
 2.05 m   
11a’ 1.83 m 60.05                                                C-7’    
12’ 2.64 m 33.14 C-11a’                                    C-11’ 
 3.04 d (15)   
12a’ - 128.87c  
12b’ - 126.63  
13’ 4.39 m 40.88 C-6’, C-13                                 C-5’, C-15’ 
14’ 4.84 t (10) 47.78                                                   C-6’, C-15          
15’ - 207.82  
16’ (CH3) 2.31 s  29.05 C-15’                                         C-14’ 
2’-OMe 3.91 s 55.75b                                                   C-2’ 
3’-OMe 3.98 s 55.81b                                                   C-3’ 
a-d signals are interchangeable. CDCl3, 600 MHz (1H), 150 MHz (13C)
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Figure 2.3 – Structure and 1H NMR spectrum of 1 
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The structure of 1 as well as its relative configuration were determined by 1D and 2D NMR data 
analysis. The relatively large molecular mass compared to known phenanthroindolizidines and 
benzopyrroloisoquinoline, as well as the presence of two sets of signals in both 13C and 1H NMR 
spectra further indicated 1 to be a dimeric molecule. The tetra-substituted cyclobutane ring (C-13 –
C-14–C-14’–C-13’), which was alluded to above, was the starting point to connect other partial 
structures together by using correlations in the HMBC spectrum. The first connections to the 
cyclobutane ring (at C-14 and C-14’) were by the two acetyl groups, i.e., the C-15–C-16 and C-15’–C-
16’ fragments, based on HMBC correlation from H-16 to C-14, and from H-16’ to C-14’. Based on the 
HMBC data, the four O-methyl singlets at H 3.76, 3.91, 3.94 and 3.98 were assigned to their place by 
the correlations observed from 2-OMe to C-2; 3-OMe to C-3; 2’-OMe to C-2’; and 3’-OMe to C-3’. 
Thus the naphthalene rings A, B, A’, and B’ were partially characterized and their connections to the 
cyclobutane ring were established by the long-range correlations from H-13 to C-5 and C-6a (for the 
B ring) and correlations from H-13’ to C-5’ and C-6a’ (for B’ ring). Due to severe overlapping of 1H 
NMR resonances, establishment of the indolizidine moieties of tengerensine (1) was not possible by 
using COSY data alone. However, the presence of 13C resonances due to two aminomethine carbons 
at C 60.05 (x 2C) as well as four aminomethylene carbons at C 55.51 (x 2C), 53.70 and 55.16, 
indicated the presence of the two indolizidine moieties fused to both of the naphthalene rings. This 
was further confirmed by comparison of the NMR data of 1 with those of fislutosine, a 
benzopyrroloisoquinone alkaloid recently obtained from another Ficus species (Table 2.3).43 The 
structure proposed is consistent with the molecular formula established by the HRESIMS 
measurements as well as the full HMBC data. The gross structure of tengerensine (1) is shown in 
Figure 2.2, while Figure 2.4 shows the key HMBC correlations.  
 
Figure 2.4 – Selected HMBC’s of 1 
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Table 2.3 -  Comparison of NMR data between 1 and fistulosine.43  
Tengerensine (1) Fistulosine  
Position 1H 13C Position 1H 13C Position 1H 13C 
1 6.96 s 101.51 1’ 6.96 s 101.85 1 7.15, s 103.2 
2 - 149.36 2’ - 149.19 2  150.5 
3 - 148.59 3’ - 148.79 3  150.0 
4 6.55 s 106.98 4’ 7.04 s 106.73 4 7.11, s 108.0 
4a - 128.98c  4a’ - 129.67c 4a  128.6 
5 6.94 s 124.84 5’ 7.51 s 123.02 5 7.56, s 124.7 
6 - 129.26 6’ - 130.87 6  134.9 
6a - 126.94c 6a’ - 127.38c 6a  129.9 
7 3.47 m 55.51a 7’ 2.75 d 
(14.5) 
53.70 7 3.43 d   
(14.9)  
53.8 
 4.37 d 
(13.7) 
  4.16 d 
(14.5) 
  4.28 d 
 (14.9) 
 
9 2.33 m 55.51a 9’ 2.16 m 55.16a 9 2.35 q 55.7 
 3.43 m   3.34 m   3.37 s  
10 1.82 md 21.55 10’ 1.95 md 21.55 10 1.91 m 22.5 
 1.92 md   2.04 md   2.01 m  
11 
 
 
1.70 m 31.14a 11’ 1.58 m 31.14a 11 1.72 m 32.2 
 2.19 m   2.05 m   2.23, m  
11a 2.16 m 60.05b 11a’ 1.83 m 60.05b 11a 2.43, m 61.2 
12 2.74 m 33.51 12’ 2.64 m 33.14 12 2.87, m 
 
34.0 
 3.16 dd 
(15, 2)  
  3.04 d 
(15) 
  3.37, m  
12a - 128.67c 12a’ - 128.87c 12a - 129.9 
12b - 126.53 12b’ - 126.63 12b - 128.2 
13 4.54 t 
(10) 
39.42 13’ 4.39 m 40.88 13 4.70 s 64.1 
14 4.02 t 
(10) 
50.60 14’ 4.84 t 
(10) 
47.78 - -  
15 - 206.27 15’ - 207.82 - - - 
16 1.65 s 28.43 16’ 2.31 s 29.05 - - - 
2-OMe 3.94 s 55.69b 2’-OMe 3.91 s 55.75b 2-OMe 4.02 s 56.8 
3-OMe 3.76 s 55.75b 3’-OMe 3.98 s 55.81b 3-OMe 4.00 s 56.8 
a-d signals are interchangeable  
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The relative configuration of tengerensine (1) was determined using the key NOESY correlations 
observed for hydrogens attached to the stereogenic centres C-13, C-14, C-14’ and C-13’. NOESY 
correlations from H-5 and H-5' to H-14' as well as from H-7 to H-7' suggests that the two indolizidine 
partial structures of the benzopyrroloisoquinoline moieties were pointing toward one another, while 
the naphthalenyl part of the benzopyrroloisoquinoline moieties were pointing away from each 
other. NOESY correlations from H-5 and H-5' to H-14' also indicates that both the 
benzopyrroloisoquinoline moieties are on the same face of the cyclobutane ring, i.e., both H-13 and 
H-13' are cis to each other. NOESY correlations from H-7’ to H-13 and H-13’ further confirmed the 
previous statement. On the other hand, the absence of NOESY correlation between H-5/H-5' and H-
14 suggested that H-14 have opposite orientation to the benzopyrroloisoquinoline moieties and that 
H-14 and H-14' are trans to each other. Furthermore, the presence of NOESY correlations from H-7 
to H-13; H-5 to H-14'; H-7' to H-13'; and H-5' to H-14' dictated that both H-13' and H-14' were trans 
to each other. Taken together, it can be concluded that the cyclobutane ring in 1 was cis,trans,trans-
configured, i.e., H-13, H-14, and H-13' were on the same face, while H-14' on the opposite face of 
the cyclobutane ring (Figure 2.5). 
 
Figure 2.5 – Selected NOESY correlations of tengerensine (1) 
 
Since tengerensine (1) affords suitable crystals from CH2Cl2/CH3OH, an X-ray diffraction analysis was 
carried out. The X-ray structure (Figure 2.6) is in agreement with the proposed structure so far 
disclosed, including the relative configuration determined by the NOESY correlations. Additionally, 
the X-ray analysis showed an interesting feature in 1 where the configuration of the two 
stereocentres at C-11a and C-11a’ are opposite to each other. This means that if the buten-2-one 
side chains were to be disregarded, both monomeric benzopyrroloisoquinoline halves are in fact 
enantiomers.  
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The X-ray crystal structure (Figure 2.6) also revealed that the acetyl group at C-14 is in the vicinity of 
an aromatic shielding zone, thus providing an explanation for the notably shielded acetyl signal (H 
1.65, Me-16) observed in the 1H NMR spectrum. 
 The crystals of 1 were triclinic (crystal system having three unequal oblique axes) with a space group 
of P1 (a centrosymmetric space group), indicating a racemic mixture of two enantiomers. This is 
consistent with the fact that 1 was virtually optically inactive. Chiral HPLC separation of the two 
enantiomers was performed and afforded (+)-1 and ()-1 in a ratio of approximately 1:1 (Figure 2.7).  
 
 
Figure 2.6 – X-Ray crystal structure of (±)-tengerensine (1) obtained by single-crystal X-ray diffraction 
analysis using Cu Kα radiation 
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Figure 2.7 – Chiral HPLC chromatogram for the separation of (±)-tengerensine (1) with 1:1 
enantiomeric ratio 
 
The two separated enantiomers of (±)-tengerensine (1) were then subjected to electronic circular 
dichroism (ECD) analysis which as expected showed opposite Cotton effects (Figure 2.8). Finally, 
comparison of the experimental and calculated ECD spectra (Figure 2.7) of the enantiomers allowed 
the absolute configurations of (+)-1 and ()-1 to be established as 11aS,13S,14S,11a'R,13'R,14'S and 
11aR,13R,14R,11a'S,13'S,14'R, respectively. 
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Figure 2.8 Experimental and calculated ECD spectra of (+)-1 and ()-1. 
 
 
Cyclobutane-containing secondary metabolites occur widely in bacteria, fungi, plants and marine 
invertebrates. These compounds have an exclusive non-enzymatic biosynthetic pathway. They are 
formed by photochemical [2+2] cycloaddition reaction, a mechanism involving the reaction of two 
alkenes where the electrons of two alkene groups form two CC bonds with each other (Scheme  
2.1).76 
 
 
Scheme 2.1 – General mechanism of cyclobutane formation via 2+2 cycloaddition. 
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The stereochemistry of this non-enzymatic reaction depends on the configuration around the double 
bound of the alkene precursors (Scheme 2.2). The stereochemistry is usually symmetrical at the 
cyclobutane ring because the starting alkenes in most cases have the same configuration, i.e., either 
‘cis + cis’ or ‘trans + trans’.76 
 
 
Scheme 2.2 – Possible stereochemical outcomes of [2+2] cycloadditions  
 
In the case of tengerensine 1 the two stereoisomeric benzopyrroloisoquinoline alkene monomers 
reacting to form 1 have an opposite configuration at the C-11a stereogenic centre according to the 
X-ray data. Another key observation from the X-ray 3D structure of 1 is that the cyclobutane is 
unsymmetrical which in turn means that the two benzopyrroloisoquinoline alkene monomers are 
each incorporating either a Z- or E-double bond in the bute-2-one side chain.  
The structure of tengerensine (1) therefore represents a rare instance of an unsymmetrical 
cyclobutane dimeric adduct and the first example of a dimeric benzopyrroloisoquinoline alkaloid. A 
possible partial biosynthetic pathway is shown in Scheme 2.3. 
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Scheme 2.3 – Partial biosynthetic pathway to (±)-1.  
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2.2.2 Tengechlorenine (2)  
Alkaloid 2 was isolated as colourless crystals (mp 192 – 195 oC), with [α]D + 11.4 (c 0.08, CHCl3). The 
UV spectrum showed characteristic phenanthrene absorption maxima at 232, 269, 347.40 and 366 
nm. HRESIMS gave a protonated molecular ion peak at m/z 398.15115, which was unintelligible at 
first (Appendix B). 
The 1H NMR spectrum (Table 2.4) revealed the presence of one 1,2,4,5-tetrasubstituted benzene 
ring [9.39 (1H, s), 7.32 (1H, s)] and one 1,2,3,4-tetrasubstituted benzene ring [7.79 (1H, d, J=9), 
7.27 (1H, d, J=9)]. The signal at  9.39 indicates that the affected hydrogen is in the proximity of a 
lone-pair electrons bearing atom, where the lone-pair electrons of that atom are causing a 
paramagnetic anisotropic deshielding on that hydrogen. This phenomenon is termed paramagnetic 
anisotropic effect and it is affected by non-bonding electrons, as opposed to diamagnetic anisotropy 
which is caused by the bonding and electrons. Such significantly deshielded aromatic protons are 
associated with phenanthroindolizidines having a lone-pair bearing atom at C-5 when a hydrogen is 
present at C-4 and vice versa (Figure 2.9).53  
 
 
 
Figure 2.9 – Significantly deshielded aromatic protons due to paramagnetic anisotropic deshielding 
in 3-demethylisotylocrebrine and 6-demethyltylocrebrine   
 
Additionally, the 1H NMR spectrum showed two characteristic AX doublets at  4.62 (1H, d, J=14.8) 
and 3.66 (1H, d, J=14.8) corresponding to a pair of isolated benzylic methylene hydrogens bound to 
an electron-withdrawing heteroatom, i.e., H2C-9–N (Figure 2.10). The noticeably different chemical 
shifts of the two geminal hydrogens can be explained by their spatial orientation in the ring. The 
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proton that is closer in space to the lone pair electrons of nitrogen is significantly deshielded 
(paramagnetic deshielding).  
Table 2.4 – 1H, 13C and HMBC NMR data of 2 
Position 1H  13C HMBC 
 
1 7.32 s 103.45 C-2,C-3, C-14a, C-4a 
2 - 148.96                    
3 - 146.68  
4 9.39 s 109.83 C-3, C-2, C-4b        
4a - 123.16b  
4b - 128.34  
5 - 118.34  
6 - 153.88  
7 7.27 d (9) 111.29 C-5, C-6, C-8a 
8 7.79 d (9) 122.01 C-5, C-6, C-8b 
8a  126.31  
8b  127.79  
9 4.62 d (14.8) 54.21 C-8a, C-13a 
 3.66 d (14.8)     
11 3.45 td (8.5, 1.7) 55.08 C-12, C-13, C-13a 
 2.44 m   
12 1.92 m 21.70 C-11, C-13 
 2.02 m   
13 2.23 m 31.27 C-12 
 1.77 m   
13a 2.47 m   60.04 C-12, C-9 
14 3.29 dd (15.7, 2.4) 33.96 C-13a, C-8b 
 2.90 m   
14a  - 127.12  
14b  - 126.38b  
2-OMe 4.06 s 55.80a C-2 
3-OMe 4.08 s 56.03a C-3 
6-OMe 4.05 s 57.00 C-6 
a,b Overlapping signals, CDCl3, 600 MHz (1H), 150 MHz (13C) 
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Figure 2.10 – Structure and 1H NMR spectrum of 2
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The 1H NMR also showed three aromatic methoxy singlets at  4.05, 4.06 and 4.08. The signals 
appearing in the region between 1.0 and 4.7 ppm bear a general resemblance to those of 
phenanthroindolizidine alkaloids with an unsubstituted indolizidine moiety.41 51 
A search through the literature for phenanthroindolizidines that possess an unsubstituted 
indolizidine moiety, three aromatic methoxy groups and a paramagnetic deshielded aromatic proton 
( > 9 ppm), which are present in the 1H NMR spectrum of 2, yielded only two alkaloids, viz., 6-
demethyltylocrebrine and 3-demethylisotylocrebrine (Figure 2.9). Although both alkaloids possess 
almost identical 1H NMR spectra to that of alkaloid 2, the HRESIMS data of 2 suggested otherwise. 
Thus, more extensive study of the 2D NMR was needed to establish the structure of 2. 
The 13C NMR spectrum (Table 2.4) showed a total of 23 carbon signals. With the aid of the HSQC 
spectrum, the 23 carbon signals were determined to be due to fourteen aromatic carbons (including 
three oxygenated quaternary carbons), three methoxy carbons, five methylene (including two 
aminomethylene) carbons and one aminomethine carbon.  
The presence of the unsubstituted indolizidine moiety was further confirmed by the COSY spectrum 
that showed the partial structure NCH2CH2CH2CHCH2 which corresponds to the N–C-11–C-12–C-13–
C-13a–C14 fragment (Figure 2.11). NOESY correlations observed between H-8/H-9, H-1/H-14, 2-
OMe/H-1, 6-OMe/H-7, together with HMBC correlations from H-1 to C-3, H-4 to C-2, H-7 to C-5 and 
H-8 to C-6, unambiguously established the substitution pattern on the phenanthrene ring with the 
three methoxy groups being placed at C-2, C-3 and C-6 (Figure 2.11). To explain the noticeably 
deshielded H-4 ( 9.39) the aromatic C-5 must be substituted with a lone pair electrons bearing 
atom. However, the carbon chemical shift of C-5 was too low to be an oxygenated aromatic carbon, 
i.e., 118.34 ppm, suggesting that the substituent is a halogen atom instead. This was in agreement 
with the HRESIMS data that showed a protonated ion peaks at m/z 398.15115 and 400.15070, both 
corresponding to [C23H2435ClNO3+H]+ and [C23H2437ClNO3+H]+, with an intensity ratio of 3:1 
(confirming that 2 must contain a chlorine atom).  
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Figure 2.11 – COSY and selected HMBC’s of tengechlorenine 2 
 
The structure of 2, which was established via detailed examination of the spectroscopic data were 
further confirmed by X-ray crystallographic analysis since suitable crystals were obtained (Figure 
2.12). The crystals of 2 were triclinic with a space group of P1 (a centrosymmetric space group), 
indicating a racemic mixture of two enantiomers. However, the optical activity observed for the 
sample solution of 2, suggested that 2 existed as a mixture of enantiomers with enantiomeric excess 
of one component.  
 
 
Figure 2.12 – X-ray diffraction analysis of 2  
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The isolation of some phenanthroindolizidine alkaloids as a mixture of both enantiomers is a well-
documented phenomenon. According to literature, some naturally occurring 
phenanthroindolizidines were isolated as pairs of enantiomeric mixtures with one enantiomer being 
in slight excess, which may explain the significantly lower optical activity of those naturally isolated 
compounds compared to their pure enantiomeric synthetic counterparts. It also appeared that 
modification of the isolation process had no effect on the phenomenon, e.g., increased heating 
during extraction or isolation of the alkaloids.75  
(±)-Tengechlorenine (2) represents the first naturally occurring halogenated phenanthroindolizidine 
alkaloid to be discovered, which reopens the door for the diversity of this class of alkaloids and the 
possibilities of new and possibly more biologically active phenanthroindolizidines. 
Halogenated natural products were once considered as rare and sometimes termed as “biological 
mistakes” with only dozen known examples in the 1950s. However, by 2015 more than 5000 
halogenated natural products have been isolated and fully characterized. Multiple theories and 
evidences have been gathered and discussed to explain the biosynthesis of these compounds, such 
as, the involvement of halogenating enzymes that are either highly specific (targeting one substrate 
usually an amino acid) or less specific enzymes known as haloperoxidases (HPO).77 
As mentioned in section 1.3.2, a biosynthetic study using radiolabeled carbon was carried out and 
determined phenanthroindolizidines are derived from tyrosine, orthinine and phenylalanine. Since 
tyrosine is the primary targeted molecule of multiple FADH2-dependent plant halogenases, the 
halogenation of tyrosine probably took place in an early integrated step of this multi-enzymatic 
biosynthesis.77 Scheme 2.4 shows a possible pathway for the biosynthesis of 2.       
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Scheme 2.4 – A possible biosynthetic pathway of tengechlorenine (2) 
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2.2.3 ()-Fistulosine (3) 
Alkaloid 3 was isolated as light yellowish amorphous powder, with [α]D 0 (c 0.06, MeOH). The UV 
spectrum showed characteristic naphthalene absorption maxima at 239, 282, 314 and 328 nm. The 
IR spectrum showed a band at 3360 cm-1 due to the presence of OH group. HRESIMS measurements 
yielded the molecular formula C19H23NO3, with a protonated ion peak detected at m/z 314.1754, 
corresponding to C19H23NO3+H+ (see appendix C). The 1H, 13C NMR and HMBC data of ()-3 are shown 
in Table 2.5.  
Table 2.5 – 1H, 13C and HMBC NMR data of ()-fistulosine (3) a 
Position 1H  13C HMBC 
 
1 7.13 s 101.99 C-2,C-12b, C-4a 
2 - 149.54                    
3 - 149.00  
4 7.10 s 106.98 C-3, C-5, C-4a, C-12b        
4a - 127.63   
5 7.56 s 123.74 C-4, C-6a, C-13 
6 - 133.85  
6a - 128.99  
7 3.43 d (15) 52.70 C-6, C-6a, C-9, C-11a 
 4.28 d (15)   
9 2.36 m 54.72 C-7, C-10 
 3.35 m     
10 1.89 m 21.56 C-9, C-11 
 2.01 m   
11 1.70 m 31.26 C-9, C-10, C-11a 
 2.23 m   
11a 2.47 m 60.23  
12 2.88 m 33.02 C-6a, C-11, C-11a 
 3.33 m     
12a - 127.30  
12b - 128.23  
13 4.64 s 63.31 C-5, C-6 
2-OMe 4.00 s 55.81 C-2 
3-OMe 4.01 s 55.81 C-3 
aCDCl3, 600 MHz (1H), 150 MHz (12C) 
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Figure 2.13 – Structure and 1H NMR spectrum of ()-3 
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The 13C NMR spectrum (Table 2.5) showed 19 carbon signals corresponding to ten aromatic carbons 
(two oxygenated), two methoxy carbons, six methylene carbons (two aminomethylene and one 
hydroxymethylene) and one aminomethine carbon. The 13C resonances were therefore in agreement 
with the molecular formula established by HRESIMS.  
The 1H NMR spectrum (Figure 2.13) showed three aromatic singlets at  7.10, 7.13 and 7.56, which 
together with the 10 aromatic carbon signals observed in the 13C NMR, as well as the UV data, 
suggested that 3 has a naphthalene moiety. Two aromatic methoxy resonances at  4.00 and 4.01, 
were also observed, with each showing HMBC three-bond correlations to the aromatic C-2 and C-3 
at C 149.54 and 149.0, respectively. This readily established the placement of these methoxy groups 
at C-2 and C-3. In addition to an isolated methylene group due to C-7, the COSY data showed a 
CH2CHCH2CH2CH2 partial structure corresponding to the C-12–C-11a–C-11–C-10–C-9 fragment in 
alkaloid 3, thus confirming the presence of an indolizidine structure. The NMR data disclosed so far 
suggested that alkaloid 3 is fistulosine, a benzopyrroloisoquinoline alkaloid previously obtained from 
F. fistulosa. Finally, the structure of alkaloid 3 was confirmed by comparing its 1H and 13C NMR data 
with those previously reported for fistulosine.43 The structure proposed for alkaloid 3 was also in 
complete agreement with the HMBC data (Figure 2.14).  
 
 
 
 
Figure 2.14 – COSY and selected HMBC’s of 3 
  
 
Determination of the relative configuration at C-11a was not possible by using NMR data. Fistulosine 
was previously isolated from F. fistulosa and showing a negative optical rotation with [α]D -11 (c 0.08, 
MeOH). The three other phenanthroindolizidine alkaloids isolated in that study all showed a 
negative optical rotation and their configuration at C-11a was assigned as R. It was only by analogy 
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that (-)-fistulosine was assigned as R.43 However, alkaloid 3 obtained in the present study as a 
racemic mixture.  
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2.2.4 Antofine (4) 
Alkaloid 4 was isolated in minute amount as a light yellowish residue, with [α]D +17.5 (c 0.03, CHCl3).  
HRESIMS measurements yielded the molecular formula C23H25NO3, with a protonated ion peak 
detected at m/z 364.19150, corresponding to C23H25NO3+H+. The UV spectrum showed characteristic 
phenanthrene absorption maxima at 258, 282 and 285 nm. The 1H NMR data are shown in Table 2.6. 
 
Table 2.6 – 1H NMR data of alkaloid 4 compared to those of (+)-antofine and (+)-deoxytylophorinine 
retrieved from literature.78 79 
Position Alkaloid 4a (+)-Antofine (+)-Desoxytylophorinine 
1 7.32 s 7.32 s 7.92 d (9) 
2 - - 7.20 dd (9, 2.5) 
4 7.92 s 7.92 s 7.87 d (2.5) 
5 7.91 d (2.4) 7.91 d (2.5) 7.89 s 
        7 7.21 dd (8.9, 2.4) 7.82 dd (9.2, 2.5) - 
8 7.83 d (8.9) 7.83 d (9.2) 7.12 s  
9 4.70 d (14.8) 4.71 d (14.8) 4.57 d (15) 
3.70 d (14.8) 3.71 d (14.7) 3.61 d (15) 
11 3.46 m  3.47 m 3.46  m  
3.37 m 3.35 m 2.48 m 
12 1.92 m 1.90 m 2.01 m 
1.87 m  1.85 m 1.91 m 
13 2.20 m  2.24 m 2.21 m 
2.02 m  2.01 m 1.71 m 
13a 3.47 m 3.45 m 3.46 m 
14 3.40 m 3.40 m  3.38 dd (16, 14) 
3.37 m  3.35 m 2.91 dd (16, 2.5) 
2-OMe 4.11 s 4.11 s 4.09 s 
3-OMe 4.06 s 4.07 s 4.04 s 
6-OMe 4.02 s 4.02 s 4.00 s  
aCDCl3, 600 MHz
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Figure 2.15 – Structure and 1H NMR spectrum of 4 
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Detailed inspection of the 1H NMR data (Table 2.6) of alkaloid 4 revealed it to be a 
phenanthroindolizidine alkaloid with an unsubstituted indolizidine moiety. The presence of three 
aromatic methoxy singlets at  4.02, 4.06 and 4.11 indicated that the phenanthrene portion is 
substituted with three methoxy groups. A search through the literature based on the splitting 
patterns of the remaining five unsubstituted aromatic hydrogens in 4 suggested that it is either 
antofine78 or deoxytylophorinine79 (Figure 2.16). This inference was also supported by the molecular 
formula established for alkaloid 4. Finally, direct comparison of the 1H NMR data of 4 with those of 
antofine and deoxytylophorinine (Table 2.6) revealed alkaloid 4 to be antofine. Figure 2.15 shows 
the 1H NMR spectrum and gross structure of antofine (4). 
 
 
 
Figure 2.16 – Structures of antofine and deoxytylophorinine 
 
The stereocenter at C-13a in the structure of 4 was assigned as S due to the fact that it showed a 
positive optical rotation ([α]D +8.2), which according to literature, phenanthroindolizidines with a 
positive optical rotation have S configuration at C-13a, while those with a negative rotation have R 
configuration.41 
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2.2.5 Secoantofine (5) 
Secoantofine (5) was isolated as a colorless oil with [α]D -7.3 (c 0.15, CHCl3). HRESIMS showed the 
molecular formula to be C23H27NO3 with a protonated ion peak detected at m/z 366.2063 
corresponding to C23H27NO3+H+. The UV spectrum showed absorption maxima at 230.4 and 282.2 
nm. The 1H NMR data of 5 are shown in Table 2.7 with comparison to that of secoantofine from 
literature.80   
Table 2.7 – 1H NMR data of alkaloid 5 compared to those of secoantofine retrieved from literature.80  
Position Alkaloid 5 Secoantofine 
1 6.47 d (1.2) 6.47 d (1.1) 
4 6.66 ma 6.66 ma 
4a 6.66 ma 6.66 ma 
4b 6.69 d (AA’XX’) 6.69 d (AA’XX’) 
5 6.69 d (AA’XX’) 6.69 d (AA’XX’) 
        7 6.97 d (AA’XX’) 6.97 d (AA’XX’) 
8 6.97 d (AA’XX’)  6.97 d (AA’XX’) 
9 3.87 d (15) 3.87 d (15) 
3.08 d (16) 3.07 d (16) 
11 2.10 m  2.11 m 
3.31 m 3.29 m  
12 1.53 m 1.53 m 
2.06 m  2.06 m  
13 1.78 m  1.78 m 
2.01 m  2.01 m 
13a 2.38 m 2.36 m 
14 2.77 m 2.68 m 
2.25 m  2.25 dd (9, 9) 
MeO-2 3.81 s 3.81 s 
MeO-3 3. 73 s 3.72 s 
MeO-6 3. 55 s 3.54 s 
a Signals are overlapping. CDCl3, 600 MHz 
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       Figure 2.17 - Structure and 1H NMR spectrum of 5
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The 1H NMR spectrum of 5 (Table 2.7) showed seven aromatic signals, four of which correspond to a 
typical AA’XX’ spin system resonating at  6.97 and 6.69, suggested the presence of a 1,4-di-
substituted benzene ring, which in turn suggested that 5 is a seco-phenanthroindolizidine-type 
alkaloid.  In addition, three aromatic methoxy singlets were observed at  3.81, 3.73 and 3.55,as in 
the case with antofine (4). The presence of an unsubstituted indolizidine moiety in 5, was evident 
from the remaining 1H NMR signals as well as the corresponding splitting patterns.  
A search through the literature for seco-phenanthroindolizidine alkaloids possessing an 
unsubstituted indolizidine moiety and three aromatic methoxy substituents, yielded only the 
structure of secoantofine (Figure 2.17). Finally, the structure of 5 was unambiguously determined to 
be secoantofine by direct comparison of the 1H NMR data of 5 with those reported in the literature 
for secoantofine (Table 2.7).41 80  
Since alkaloid 5 showed a negative optical rotation, [α]D -7.3 (c 0.15, CHCl3), the configuration at C-
13a can be assigned as R.41  
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2.3 Biological Activity    
Alkaloids have been known to possess various pharmacological effects. In addition to the 
phytochemical investigation, (±)-tengerensine (1) and its enantiopure components, (±)-
tengechlorenine (2) and (±)-fistulosine (3) were assayed for cytotoxic activity. This part of the 
research was carried out by School of Pharmacy, International Medical University, Malaysia.  
(±)-Tengechlorenine 2 showed to be the most potent compound against all cell lines, while having 
little selectivity (moderately cytotoxic against non-tumorigenic breast epithelial cells). The racemic 
bisbenzopyrroloisoquinoline (±)-1 and the enantiopure component ()-1 showed weak activity with 
IC50 range between 18-46 M. However, the other enantiopure component (+)-1 showed appreciable 
cytotoxicity with IC50 7.4 M while maintaining selectivity and showing no cytotoxicity against the 
non-tumorigenic cell line. Lastly, (±)-fistulosine (3) showed no apparent cytotoxicity against all the 
tested cell lines, which is in consistence with literature that reported this group compounds as non-
cytotoxic.67 
 
Table 2.8 –  Cytotoxic effects of the isolated compounds and 5-fluorouracil (positive control) 
Alkaloid IC50 ± SD (M) 
MDA-MB-468a MDA-MB-231a MCF7a MCF-10Ab 
(±)-1 17.9 ± 3.3 37.9 ± 5.9 46.5 ± 9.6  >100 
(+)-1 7.4 ± 2.1 36.0 ± 5.6 19.0 ± 4.6 >100 
()-1 23.7 ± 3.1 37.5 ± 3.2 37.7 ± 4.3 >100 
(±)-2 0.038 ± 0.01 0.48 ± 0.05 0.91 ± 0.06 10.7 ± 3.7 
(±)-3 >100 50.3 ± 4.3 >100 >100 
5-Fluorouracil 43.3 ± 1.3 20.1 ± 1.1 24.1 ± 1.2 34.6 ± 1.2 
aMDA-MB-468, MDA-MB-231 and MCF-7 are human breast adenocarcinoma; MCF-10A is non-
tumorigenic human breast epithelial cells. 
To sum up, phenanthroindolizidines are extremely potent cytotoxic agents even at very low 
concentrations in vitro, while having no clinical value due to their non-selectivity and extreme side 
effects.56 On the other hand, although monomeric benzopyrroloisoquinolines are non-cytotoxic, the 
same cannot be said of the dimeric form as selective and moderate cytotoxic activity was observed 
for (+)-1, suggesting that enantiomerism played a role in how alkaloid 1 exert its cytotoxic effect in 
the breast cancer cell lines tested. This opens the door for future research in synthesizing analogues 
of dimeric benzopyrroloisoquinolines with the correct stereochemistry to enhance cytotoxic activity 
towards cancer cells while maintaining selectivity.  
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Chapter Three  
 
Experimental 
 
 
3.1 Plant Source and Authentication   
The plant material of Ficus fistulosa var. tengerensis was collected in Hutan Simpan Berembun, 
Negeri Sembilan, Malaysia, and was identified by Dr. K. T. Yong (Institute of Biological Science, 
University of Malaya). Voucher specimens (KLU49073, KLU49074, KLU49075 and KLU49076) are 
deposited at the Herbarium, University of Malaya. The plant material was subjected to preliminary 
screening to determine the presence of alkaloids before any large scale collection took place. The 
weight of dried leaves used was approximately 15 Kg. 
 
 3.2 General  
Melting points were determined on Electrothermal IA9100 digital melting point apparatus and are 
uncorrected. Optical rotations were determined on a JASCO P-1020 automatic digital polarimeter. IR 
spectra were recorded on a PerkinElmer Spectrum 400 FT-IR/FT-FIR spectrophotometer. UV spectra 
were obtained on a Shimadzu UV-3101PC spectrophotometer using absolute ethanol. 1H and 13C 
NMR spectra were recorded in CDCl3 using TMS as internal standard on Bruker 600 MHz and 150 
MHz spectrometer. HRESIMS were obtained on a JEOL Accu TOF-DART mass spectrometer. Chiral 
HPLC was performed on a Waters liquid chromatograph with a Waters 600 controller and a Waters 
2489 tunable absorbance detector. A Chiralpak AS-H column (4.6 × 150 mm, Daicel, Japan) packed 
with amylose tris[(S)-α methylbenzylcarbamate] coated on 5 µm silica gel was used, at ambient 
temperature, and fractions were collected manually. ECD spectra were obtained on a J-815 Circular 
Dichroism Spectrometer. X-ray diffraction analysis was carried out on a Rigaku Oxford (formerly 
Agilent Technologies) SuperNova Dual diffractometer with Cu Kα (λ = 1.54184 Å) radiation at rt. The 
structures were solved by direct methods (SHELXS-2014) and refined with fullmatrix least-squares on 
F2 (SHELXL-2014). All non-hydrogen atoms were refined anisotropically, and all hydrogen atoms 
were placed in idealized positions and refined as riding atoms with the relative isotropic parameters. 
All solvents used throughout this research were analytical grade and during bulk extraction distilled 
ethanol was used. HPLC grade solvents were used when the chiral HPLC analysis was carried out.  
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3.3 Extraction of Alkaloids   
The collected leaves of F. fistulosa var. tengerensis (15 kg) were left to dry indoors. The dried leaves 
were then coarsely ground and extracted by adding 95% ethanol and soaking the leaf material for 
two days at room temperature. The ethanol extract was then decanted and subjected to rotary 
evaporation to concentrate the extract. The plant material was then re-extracted with another batch 
of distilled 95% ethanol and this process was repeated four times. The concentrated combined bulk 
ethanolic extract was subjected to acid-base treatment to selectively extract alkaloids from the bulk 
crude extract. Firstly, the crude extract was added to 1 L of 2% tartaric acid solution with vigorous 
stirring in a 5 L conical flask. The acidic solution was then filtered through Kieselghur to get rid of any 
insoluble material that was regarded as non-alkaloidal substances. The pH of the filtered acidic 
solution was then adjusted to about 10 by the addition of concentrated ammonia solution. The 
basified solution was extracted with ethyl acetate (1:1 volume ratio, three times). The combined 
ethyl acetate extract was partially concentrated and treated with sodium sulphate anhydrous. 
Finally, the ethyl acetate solution was dried using rotary evaporator to yield the crude alkaloidal 
extract of 10.45 g.  
 
3.4 Chromatographic Techniques  
Various chromatographic methods were employed on the crude alkaloidal extract until pure 
alkaloids were obtained. Methods including column chromatography, thin layer chromatography, 
centrifugal thin layer chromatography and HPLC. 
3.4.1 Column Chromatography  
i. Vacuum Column Chromatography (VCC): 
VCC was used to fractionate the alkaloid crude extract (10.045 g) using Merck silica gel 60 (0.040 – 
0.063 mm) at approximately 20:1 silica to sample ratio. The silica was made into slurry and packed 
into the column under vacuum with repeated solvent refills until sufficient packing was achieved and 
the column was equilibrated. The sample was dissolved in minimum amount of solvent and with the 
least possible polarity. The sample solution was then pipetted gently onto the silica bed. The sample 
was then eluted using CHCl3/Hex at 4:1 ratio while gradually increasing polarity using methanol. The 
collected eluents were monitored using TLC.  
ii. Flash Column Chromatography (FCC): 
FCC was used on sub-fractions obtained from VLC which were too much to be separated using 
centrifugal thin layer chromatography i.e. sample weight >800 mg. Merck silica gel 60 (0.04 – 0.06 
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mm) or Scharlab Silica Gel 60 (0.04-0.06 mm) were used at approximately 80:1 silica to sample ratio. 
Slurry packing was performed while gently tapping the column with a thick rubber to ensure tight 
packing. After the sample was applied the column was filled with solvent and air pump was used by 
placing it on the top of the column. Gradient elution was used and the collected eluents were 
monitored using TLC. 
 
3.4.2 Thin Layer Chromatography  
Thin Layer Chromatography was the most used procedure for qualitative analysis during isolation 
steps. It was used for a number of purposes, namely, to monitor and detect the presence of alkaloids 
within samples; to find the most optimum starting solvent for both column chromatography and 
preparative centrifugal thin layer chromatography; and to check for the purity of collected fractions. 
By using this technique, the collected fractions that showed similar profiles were combined together. 
Samples were spotted onto 2.5 cm x 10 cm aluminium sheets which had been pre-coated with silica 
gel 60 F254 of 0.25 mm thickness (Merck). Samples were spotted using a glass pipette. Once the 
samples had been loaded onto the plates, the plates were then placed in saturated chromatographic 
tanks which contained different solvent systems. The plates were then removed from the tanks 
when the solvent front was 1 cm away from the end of the plate. The plate was then examined using 
a UV lamp with UV light (254nm). This caused the visualisation of molecules as dark spots. These 
spots were then drawn around using a pencil and the plate then sprayed with Dragendorff’s reagent. 
The spots which reacted with the reagent turned orange and indicated the presence of alkaloids. The 
addition of 1% ammonia was necessary in most cases to overcome the ‘tailing’ of the spots which 
appeared in majority of the fractions. The ‘tailing’ of the compounds on TLC is caused by the 
protonation of the nitrogen in the alkaloids, by the acidic silica stationary phase. Some of the 
solvents that were used as a mobile phase in TLC: 
a) Chloroform  
b) Diethyl Ether  
c) Ethyl Acetate  
 
3.4.3 Centrifugal Thin Layer Chromatography (CTLC) 
Preparative Centrifugal Thin Layer was carried out using a circular chromatographic plate measuring 
24 cm in diameter with the action of a centrifugal force to speed up mobile phase flow across the 
circular plate. To prepare the chromatographic plate, the edge of the plate was secured with 
cellophane tape to form a mould. Silica gel (Kieselgel 60 PF256, Merck, 40 g) was added to about 90 
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mL of cold distilled water in case of preparing 1 mm thick plate. The 2 mm plate was prepared by 
mixing 60 g of silica powder with 110 mL cold water. This slurry was shaken vigorously and was then 
quickly poured onto the circular glass plate before setting commences. The circular glass plate was 
then manually rotated while the gel was being poured to obtain an even setting. The plate was then 
left to air-dry for about an hour before being dried in an oven at about 55˚C overnight. Before the 
plate was used it was activated at 100 ˚C for one hour. After the activation is completed the plate is 
left outside to cool down for few minutes then using the proper blade it was shaved to the required 
size 1 mm or 2 mm. The chromatotron was then cleaned using solvents like acetone before placing 
the plate. The sample was dissolved in a minimum volume of a suitable solvent and loaded at the 
centre of the plate while the plate was spinning to form a thin band. Elution was then carried out 
with the appropriate solvent system. Fractions were collected, concentrated by rotary evaporator, 
examined by TLC and combining of similar fractions was then done when needed.  
Some of the solvent systems used as eluents were: 
1. Chloroform: Hexane with 1% ammonia 
2. Chloroform: Methanol  
3. Diethyl ether: Methanol with 1% ammonia 
4. THF: Hex with 1% ammonia 
5. THF: Methanol  
All CTLC runs were made using an increased methanol gradient to up to 35%. 
 
3.5 Spray Reagent  
Dragendorff’s reagent was used to detect the presence of alkaloids within a sample and it composed 
of the following: 
Solution A: 850 mg of bismuth subnitrate was mixed with 40 mL of water and 10 mL of glacial acetic 
acid. 
Solution B: 20 g of potassium iodide was dissolved in 50 mL of water. 
 
In order to make the reagent, equal proportions of solutions A and B were mixed together. This 
produced a stock solution which can be stored for several months in a dark bottle. Then 10 mL of the 
stock solution was mixed with 20 mL of glacial acetic acid and diluted with water up to 100 mL. This 
solution was poured into the spray bottle.   
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3.6 Isolation of Alkaloids 
The basic crude alkaloidal mixture of 10.45 g obtained from the extraction procedure described 
above was initially fractionated by vacuum column chromatography over silica gel. The column was 
eluted with chloroform, followed by a stepwise increase of methanol gradient. TLC was 
used to monitor the progress of the fractionation. Based on TLC, the many fractions 
collected were pooled into several major fractions, i.e., 11 fractions altogether, namely, FT1 – FT11. 
The combined fractions were then subjected to further purification by flash column chromatography 
or preparative centrifugal TLC. A flow diagram of the isolation procedure of the pure alkaloids is 
shown in figure 3.1. 
 
 
 
Figure 3.1 – Isolation of alkaloids from the leaves of F. fistulosa var. tengerensis  
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Separation of Enantiomers (+)-1 and ()-1 by Chiral-Phase HPLC 
(±)-Tengerensine (1) (2.3 mg) was dissolved in EtOH (0.75 mL) and resolved using a chiral column 
(eluting solvent: n-hexane/EtOH/Et2NH, 85:15:0.1; flow rate 1.0 mL/min; 150 injections, 5.0 μL each) 
to yield two fractions. Fraction 1: retention time 10 min 58 s, 0.9 mg. Fraction 2: retention time 18 
min 32 s, 1.2 mg. 
 
3.7 Compound Data  
(±)-Tengerensine (1): light yellowish block crystals; mp > 190 ºC (dec); [α]25D 0.7 (c 0.30, CHCl3); UV 
(EtOH), λmax (log ε) 239 (4.62), 280 (4.13), 332 (3.89) nm; IR (dry film) νmax 1705 cm-1; HRESIMS m/z: 
703.3752 [M+H]+ (calcd. for C44H50N2O6 + H, 703.3747); 1H ,13C and HMBC NMR data, Table 2.2. (+)-
Tengerensine (1) (Fraction 1): [α]25D +62 (c 0.02, CHCl3); ()-Tengerensine (1) (Fraction 2): [α]25D 58 
(c 0.06, CHCl3). 
Crystallographic data of (±)-1: light yellowish blocks, C44H50N2O6, Mr = 702.86, triclinic, space group 
P−1, a = 12.709(2) Å, b = 12.8666(12) Å, c = 14.9876(16) Å, α = 112.962(10) o, β = 111.821(16) o, γ = 
90.977(11) o, V = 2057.0(5) Å3, Z = 2, Dcalcd = 1.135 gcm−3, crystal size 0.40 x 0.15 x 0.02 mm3, F(000) = 
752, Cu Kα radiation (λ = 1.54178 Å), T = 293 K. The final R1 value is 0.0856 (wR2 = 0.2399) for 7852 
reflections [I>2σ(I)]. 
 
(±)-Tengechlorenine (2): colorless crystals; mp 192 – 195 oC; [α]25D +11.4 (c 0.08, CHCl3); UV (EtOH), 
λmax (log ε) 231.4 (3.47), 269 (3.68), 347.40 (2.76), 366 (2.58) nm; HRESIMS m/z: 398.15115 [M+H]+ 
(calcd. for C23H24ClNO3 + H, 398.15230); 1H, 13C and HMBC NMR data, Table 2.4. 
Crystallographic data of (±)-2: light yellowish plates, C23H24NO3Cl, Mr = 397.88, triclinic, space group 
P−1, a = 8.7014(6) Å, b = 10.2583(7) Å, c = 11.1747(8) Å, α = 99.612(6)o, β = 106.611(6)o, γ = 
93.943(6)o, V = 935.23(12) Å3, Z = 2, Dcalcd = 1.413 gcm−3, crystal size 0.1 x 0.1 x 0.01 mm3, F(000) = 
420, Cu Kα radiation (λ = 1.54178 Å), T = 165 K. The final R1 value is 0.0761 (wR2 = 1841) for 3723 
reflections [I>2σ(I)]. 
 
(±)-Fistulosine (3): light yellowish amorphous powder; [α]25D 0 (c 0.06, MeOH); UV (EtOH), λmax (log ε) 
239 (3.78), 281.8 (3.43), 313.8 (2.85), 328.4 (2.60) nm; IR (dry film) νmax 3360 cm-1; HRESIMS m/z: 
314.1754 [M+H]+ (calcd. for C19H23N1O3+H, 314.1756); 1H, 13C, HMBC NMR data, Table 2.5. 
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Antofine (4): light yellowish oil [α]25D +17.5 (c 0.025, CHCl3); UV (EtOH), λmax (log ε) 258 (4.41), 282.2 
(4.29), 285 (4.27) nm; HRESIMS m/z: 364.19150 [M+H]+ (calcd. For C23H25NO3+H, 364.19127); 1H NMR 
data, Table 2.6. 
 
Secoantofine (5): colourless oil [α]25D 7.3 (c 0.15, CHCl3); UV (EtOH), λmax (log ε) 230.4 (3.66) and 
282.2 (3.41) nm; HRESIMS m/z: 366.20633 [M+H]+ (calcd for C23H27NO3+H, 366.20692); 1H NMR data, 
Table 2.6. 
 
 
 
3.8 Cytotoxicity Assay 
Cell lines and cell culture 
A panel of human breast cancer cell lines (MCF7, MDA-MB-231, MDA-MB-468) and human non-
tumorigenic breast epithelial cells (MCF10A) were purchased from the American Type Culture 
Collection. All cancer cells were maintained in RPMI 1640 medium with 10% fetal bovine serum 
(FBS), 100 IU/mL penicillin, and 100 µg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA) while 
MCF10A cells were cultured with 5% horse serum, 20 ng/mL epidermal growth factor, 0.5 µg/mL 
hydrocortisone, 10 µg/mL insulin, 100 IU/mL penicillin, and 100 µg/mL streptomycin. All cells were 
maintained in an incubator at 37°C and 5% carbon dioxide. 
Luminescent cell viability assay 
Cell viability of cells after treatment with (±)-1, (+)-1, ()-1, (±)-3 and 5-fluorouracil (positive control) 
were determined using the CellTitre-Glo® Luminescent Cell Viability Assay kit (Promega, USA). All 
compounds were prepared in 100mM DMSO as stock solution and diluted to various concentrations 
(1.5 to 100 µM) using sterile phosphate buffer solution. All cancer or noncancer cells were seeded in 
384-well opaque plates for 24 h at a density of 1000 cells/well and followed by treatment with (±)-1, 
(+)-1, ()-1, (±)-3 and 5-fluorouracil (positive control) for 72 hours. Cells treated with 0.1% DMSO 
were the negative controls. Luminescence reading was measured using SpectraMax M3 Multi-Mode 
Microplate Reader (Radnor, USA). The inhibitory concentration of 50% cell viability (IC50) was 
determined based on the luminescent reading of treated cells and cells treated with negative 
control. 
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